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Chapter 1 
 
 
Outline of this Thesis 
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The studies in this thesis began with the observation that the mitotic checkpoint protein 
BubR1 was mutated in two of 19 cell lines established from human patients with colon 
cancer [1]. We set out to determine the physiological role of BubR1 in normal and 
malignant cell growth. To this end, we used a gene targeting strategy to create a 
hypomorphic BubR1 allele in mouse embryonic stem (ES) cells. We found that mice that 
are homozygous for this hypomorphic allele express very low amounts of BubR1 protein 
and cells from these animals undergo frequent chromosome missegregation and develop 
severe aneuploidy. These mice are also more susceptible to carcinogen-induced 
tumorigenesis, although the incidence of spontaneous tumor formation remained very low. 
Surprisingly, we found that BubR1 hypomorphic mice exhibit a variety of progeroid 
features, including reduced lifespan, cachetic dwarfism, lordokyphosis (abnormal rearward 
curvature of the spine), muscle atrophy (sarcopenia), cataracts, craniofacial dysmorphisms, 
heart arrhythmias, arterial stiffening, loss of subcutaneous body fat, and impaired wound 
healing. These findings were strengthened by a recent discovery of biallelic BubR1 
mutations in patients with mosaic variegated aneuploidy (MVA) syndrome, a recessive 
disorder characterized by aneuploidy, tumor susceptibility and progeroid features [2]. Thus, 
BubR1 appears to behave as both a suppressor of tumor formation and aging (Chapter 3). 
 
BubR1 hypomorphic mice die at a very early age with a decline in overall health. To 
determine if these mutants exhibit physiological consequences of low amounts of BubR1 in 
the vasculature, we performed a series of experiments. We found that BubR1 mutant mice 
have reduced arterial wall thickness and low numbers of smooth muscle cells. These mice 
also had profound arterial fibrosis, and consistent with these findings, had a profound 
reduction in elasticity. Importantly, the expression of BubR1 in aortas of wild-type mice 
declines significantly with age, suggesting that BubR1 may play a natural role in the 
suppressing the aging process in the vasculature (Chapter 4). 
 
We were interested in establishing the mechanism by which reduced BubR1 expression 
promotes cancer and aging. Various effectors of cellular senescence are induced when 
BubR1 levels decline, including p53, p21Cip1, p19Arf, and p16Ink4a. We first sought to 
determine the contribution of the pRb-p16Ink4a pathway in the development of progeroid 
phenotypes in hypomorphic BubR1 mice. Recent work has shown that p16Ink4a null mice 
have delayed age-related changes in specific cell types, including pancreatic islet cells 
regenerative potential [3], forebrain progenitor cell depletion [4], and hematopoietic stem 
cell maintenance [5]. Several tissues of BubR1 hypomorphic mice have elevated levels of 
p16Ink4A, including fat tissue, skeletal muscle, and the eye. By using p16Ink4a knockout mice, 
we show that loss of this tumor suppressor accelerates lung tumorigenesis and prevents the 
development of a subset of age-related disorders in BubR1 hypomorphic mice, including 
muscle atrophy, lordokyphosis, cataracts, and loss of adipose tissue. These findings suggest 
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that, in certain cell types, in tissues that display age-related pathologies that also have 
elevated levels of p16Ink4A benefit by the disruption of this gene. However, low amounts of 
BubR1 synergize with p16Ink4A deficiency to promote lung tumorigenesis specifically 
(Chapter 5). After discovering that the Rb-p16Ink4a pathway is required for the 
establishment of certain age-related characteristics in hypomorphic BubR1 mice, we then 
were interested to determine whether disruption of the p53-p19Arf pathway was able to 
modulate the development of progeroid features. It has been difficult to establish whether 
p53 or p19Arf contribute to the process of natural aging, as disruption leads to early 
tumorigenesis. By using our mouse model, we found that disruption of p19Arf leads to an 
earlier onset of aging in several tissues. This earlier onset of age-related diseases appears to 
result from an increased rate of cellular senescence when p19Arf is lacking in hypomorphic 
BubR1 mice. This suggests that p19Arf is upregulated in an attempt to combat the process 
of aging, whereas elevated levels of p16Ink4A act to promote aging processes (Chapter 5). 
 
After discovering that BubR1 was implicated in aging, we then asked if aging was a 
general consequence of impaired spindle assembly checkpoint function by using mice with 
mutations in other mitotic checkpoint proteins. We used mice that were haploinsufficient 
for Bub3 or Rae1 and found that these mice, despite developing an increase in aneuploidy, 
both in vitro and in vivo, were not predisposed to spontaneous tumorigenesis, despite the 
fact that both models had a clear susceptibility to carcinogen induced tumor formation [6]. 
These mice also displayed no overt acceleration to the development of age-related features 
that are also detectable in wild-type mice of advanced age. However, mice that were 
compound haplo-insufficient for both Bub3 and Rae1 did have accelerated aging in certain 
tissues, although the onset was substantially delayed in comparison to hypomorphic BubR1 
mice. We also found that cells from combined haplo-insufficient Bub3/Rae1 mice exhibit 
premature cellular senescence. Combined, the results from these experiments, along with 
the findings from the BubR1 hypomorphic model, suggest that early onset of aging-related 
phenotypes in mice with mitotic checkpoint defects is linked to cellular senescence and 
activation of the p53 and p16Ink4a pathways rather than to aneuploidy (Chapter 6). 
 
Rae1 and Nup98, two proteins that play key roles in regulation of mRNA export from the 
nucleus during interphase, also are involved maintenance of genomic stability [6, 7]. Cells 
that have only one functional copy of Rae1 and Nup98 are highly aneuploid [7]. To 
determine the consequences of this aneuploidy in vivo, we monitored a cohort of double 
haplo-insufficient Nup98/Rae1 mice. We found that although these mice are susceptible to 
DMBA induced tumorigenesis, they do not have an increase in spontaneous tumor 
formation, which is similar to the results we obtained when looking at Bub3/Rae1 double 
haploinsufficient mice. These data demonstrate a common theme that although mice may 
 13 
be predisposed to tumor formation when challenged with carcinogens, these cooperating 
events may not occur under normal situations in their lifespan (Chapter 7). 
 
Bub1, a BubR1-related checkpoint gene which is mutated or expressed at lower levels in a 
variety of human tumors [1, 8-13], plays many roles during mitosis to ensure accurate 
chromosome segregation. To determine the physiological role of Bub1, we generated a 
series of mice in which the expression of Bub1 is reduced in graded fashion by the use of 
wild-type, hypomorphic, and knockout alleles. We find that Bub1 null mice are 
embryonically lethal, but that Bub1 hypomorphic mice with very low levels of wild-type 
Bub1 protein are viable. We show that Bub1 prevents aneuploidy and spontaneous tumor 
development in a dose dependent fashion, and we provide evidence for a novel role of 
Bub1 in eliminating cells that have undergone chromosome missegregation (Chapter 8). 
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2.1  THE CELL CYCLE 
 
2.1.1  Introduction 
A requisite for cellular reproduction is the duplication of all cellular components, including 
genetic material, followed by an equal division into two daughter cells. For unicellular 
organisms, this process results in the creation of an additional organism. In higher 
organisms, many rounds of cell division are required to both create and maintain an 
individual. Human adults have a variety of tissues containing cells that turn over with high 
frequency, and loss of division in these cells can cause death in a short period of time. The 
process of this cell-division cycle, simply called the cell cycle, is the fundamental means by 
which all living organisms are propagated and preserved.  
 
2.1.2  Stages of the cell cycle 
The process of cell division consists of four phases: G1, S, G2 and M (Fig. 1) [1]. First, the 
cell prepares for DNA duplication by growing throughout the interval of G1, which is the 
first gap phase of the cell cycle that occurs between the end of mitosis and the beginning of 
S phase [1]. Next, replication of DNA occurs during S phase, which lasts for 10-12 hours 
in a typical mammalian cell and results in two complete sets of DNA. During G2, the 
second gap phase, the cell assures that all necessary components for traversing into and 
through mitosis are present [1]. The three phases of G1, S, and G2 are commonly referred to 
as interphase [2]. The separation of duplicated sets of DNA into daughter cells occurs 
during M phase, which can take less than an hour to complete in mammals. After mitosis, 
cells may enter into a quiescent resting state referred to as G0 where they have the capacity 
to remain uncommitted to resume the cell cycle [3, 4]. This delay may last for several years 
in some human cells, as is the case for neurons. Cells in G0 have the potential to re-enter 
the cell cycle by the tightly regulated process of mitogenic stimulation [5].  
 
2.1.3  Mitosis 
The M phase of the cell cycle can be further divided into 6 major stages and must occur in 
sequential order (Fig. 1) [6]. These stages are prophase, prometaphase, metaphase, 
anaphase, telophase and cytokinesis [7]. In early prophase, duplicated centrosomes separate 
and move towards opposite poles of the cell and DNA begins to condense. At late 
prophase, the DNA is highly condensed, with the two chromatids from each chromosome 
held tightly together. Prometaphase begins when the nuclear envelope breaks down. This 
liberation of genetic material into the mitotic cytosol allows for DNA to attach to 
microtubules originating from the centrosomes/spindle poles. At metaphase, the sister 
chromatids align at the metaphase plate, which lies at the equator between the two poles. 
The sister chromatids are attached to opposite poles by spindle microtubules bound to the 
kinetochore, a highly specialized centromeric protein-rich area that will be expanded upon 
later. Anaphase occurs when the sister chromatids separate completely and move towards 
opposite poles of the cell. Microtubules disassemble during telophase and chromosomal 
movement is completed, followed by formation of a new nuclear envelope. This event 
marks the end of mitosis. Finally, the cytoplasm divides during cytokinesis, with each 
daughter cell receiving cytoplasmic contents from the progenitor cell [8]. The completion 
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of cytokinesis marks the end of M phase and the two daughter cells can now themselves 
enter new rounds of the cell cycle [7].  
 
Aberrant maintenance in 
genetic integrity or 
missegregation of 
duplicated DNA may 
unfortunately result in 
tumor initiation. Point 
mutations, which are 
single DNA base-pair 
replacements, have the 
potential to begin the 
multi-step process of 
tumorigenesis by 
converting a normal 
functioning gene into 
potent oncogene. In a 
variety of human tumors 
for example, there are 
frequent single-nucleotide 
alterations in members of 
the Ras family, a group of 
proteins which promote 
proliferation when the 
proper mitogenic signals 
are received by receptor 
tyrosine-kinases [9]. 
These point mutations 
render Ras molecules that 
are unable to be switched 
off after the mitogenic 
signal is removed, 
resulting in an endless promotion of the proliferation signal [9]. Larger alterations in DNA 
integrity constitute the condition of aneuploidy. This is a general term that is utilized for 
describing several DNA abnormalities, which can cause confusion. In the literature, 
structural aberrations of DNA including inversions, duplications, translocations, and 
deletions are often collectively referred to as aneuploidy [10]. However, in this thesis, 
aneuploidy will refer specifically to cells that have a non-modal chromosome number. In 
normal human cells, the total number of chromosomes is 46 (23 pairs). Therefore, cells 
with more or less than 46 chromosomes are called aneuploid. Additionally, a cell may have 
46 total chromosomes, but it may be lacking one copy of a particular chromosome with a 
gain of additional one. Based on our description, this cell would also be considered 
aneuploid, as it contains a non-modal number of chromosome pairs. The condition of 
numerical aneuploidy is seen in the vast majority of human cancers [10], but whether it is a 
 
 
 
Fig. 1- Checkpoints during the cell cycle. The mammalian cycle of 
growth and division is divided into four phases, G1, S, G2, and M. A 
fifth state, G0, is a resting, non-proliferating state where cells withdrawn 
from the active cell cycle. M phase is further divided into 6 distinct 
stages. They occur in the following order: 1) prophase, 2) 
prometaphase, 3) metaphase, 4) anaphase, 5) telophase, and 6) 
cytokinesis. Checkpoints impose quality control to ensure that a cell has 
completed all the requisite steps of one phase of the cell cycle before it 
is allowed to enter into the next phase. The four main cell cycle 
checkpoints are the G1-S, S phase, G2-M, and spindle assembly 
checkpoint. 
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cause or consequence of the tumor process remains a topic of intense debate. Cells that 
contain multiple sets of complete DNA material, or polyploidy, are a unique form of 
aneuploidy [11, 12]. Several cellular defense mechanisms, including those called 
checkpoints, exist to prevent genetic aberrations such as the development of aneuploidy. 
 
2.1.4  Cell cycle checkpoints 
The strict maintenance of genetic integrity is crucial for proper cellular function. In the 
process of DNA replication during S phase, endogenous damage can occur which produces 
a variety of errors, including mismatched bases, as well as single and double strand breaks 
[13]. Exogenous agents (external exposures) can also directly damage nucleotides or break 
the phosphodiester backbone [14]. Fortunately, the cell has devised multiple ways to deal 
with this constant barrage of attacks, which includes several elegant DNA-repair processes 
[15-19]. Unfortunately, these repair processes are not perfect, and damaged DNA can be 
propagated after stable incorporation into the genome. In order to allow sufficient time for 
complete correction of severe damage to DNA, a stoppage of the cell cycle may occur 
while the process of DNA repair occurs. Apoptosis, or programmed cell death, may occur 
if the damage is deemed irreparable. Checkpoints differ from DNA repair processes, in that 
they are “scheduled stops” during the cell cycle, where the maintenance of genetic stability 
is ensured by intricate surveillance machinery [14, 15]. Many of the key proteins that 
contribute to these checkpoints have been well characterized, which will be discussed in 
detail later. Checkpoints exist to ensure that once a particular step in the cell cycle has been 
completed, it will not be repeated until the following cell cycle. The four main cell cycle 
checkpoints are the G1-S checkpoint, the S phase checkpoint, the G2-M checkpoint, and the 
spindle assembly/mitotic checkpoint (Fig. 1) [15, 20, 21]. The G1-S checkpoint ensures that 
cells that require genome repair do not enter into S phase from G1. In the S phase 
checkpoint, DNA replication will be stalled or delayed in response to significant damage to 
DNA. The third checkpoint will not permit a cell to transition from G2 into M until the 
complete replication of DNA has occurred during S phase. The spindle assembly 
checkpoint, which blocks the entry into anaphase until all chromosomes are properly 
attached to the mitotic spindle, is the main focus of this work and will be expanded upon 
later. In addition to the spindle assembly checkpoint during M, a decatenation checkpoint 
exists in late G2 to prevent entry into mitosis until the replicated pair of DNA-helices has 
been untangled from each other [22]. These checkpoints ensure that a cell is ready to move 
into the next stage of the cell cycle. Progression through the cell cycle itself is 
accomplished by an intricate network of kinases, whose activity is regulated by a class of 
proteins referred to as cyclins. 
 
2.1.5  Controlling the cell cycle 
The cell cycle requires the coordinated activity of cyclin-dependent kinases, or Cdks, for 
cycle progression [1, 23]. Active Cdks are composed of at least two subunits, a Cdk and a 
regulatory cyclin, but often contain other proteins as well [23]. Cdks have catalytic activity 
for phosphorylating serine and threonine residues on target proteins [1]. At least 11 
vertebrate Cdks have so far been identified, each with an activity that is restricted to a 
distinct portion of the cell cycle [24, 25]. The activity of Cdks is kept under tight control, 
for improper activation would lead to aberrant cell cycle progression [1, 24]. The critical 
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Fig. 2- Cell cycle pairing of cyclins (half circles) with cyclin-dependent 
kinases (rectangles). D type cyclins associate with Cdk4 or Cdk6, E type 
cyclins bind to Cdk2, A type cyclins bind to Cdk1 and Cdk2, and B type 
cyclins bind to Cdk1. Brackets indicate periods during the cell cycle where 
these various complexes are present and active. 
regulation of Cdk activity is performed largely by cyclins, but there are additional 
mechanisms to control Cdks. These include activation by phosphorylation and inhibition by 
binding of inhibitory proteins. 
 
The first cyclin was 
discovered in 1982 by a 
marine biologist who 
noted that the level of 
this protein increased 
and decreased during 
certain periods of the 
cell cycle [26]. The 
protein accumulated 
throughout interphase, 
but was abruptly 
degraded in mitosis [27, 
28]. This fluctuation in 
protein level is cyclical 
during a standard cell 
cycle; therefore it has 
been given the general 
name cyclin [1, 26, 29]. 
All cyclins share a 
conserved stretch of 
150 amino acids termed 
the “cyclin box”. This 
domain is formed by five helical regions that allows for the interaction of these proteins 
with various proteins, including Cdks. Their binding to the properly phosphorylated Cdk is 
necessary for complete Cdk activation [1]. In a recent genetic screen of the human genome, 
31 proteins were found to contain the “cyclin box” motif and have generically been termed 
cyclins of various families, although it is not known for several of these proteins if they are 
synthesized and destroyed cyclically [25]. Cdk4 and Cdk6 are two similarly acting Cdks 
that function during G1 which bind to cyclins of the D and E family (Fig. 2). An important 
cellular decision occurs late in G1 at the restriction or R point. Transitioning through the R 
point marks the switch to a mitogen-independent growth state and a commitment to 
replication of DNA and subsequent cellular division [30]. Cdk2 associates with E type 
cyclin late in G1 until A type cyclins replace these E cyclins in S phase. In late S, Cdk1 
replaces Cdk2 in cyclin A containing complexes. Finally, B-type cyclins replace cyclin A 
in Cdk1 complexes during M. The activity of the various Cdk-cyclin bimolecular 
complexes, which occur at distinct periods of the cell cycle, are responsible for sending out 
the signals that are required for traversing through the cell cycle. In order to prevent 
aberrant Cdk activity, the highly regulated process of cyclin degradation occurs, which 
cripples the catalytic activity of Cdk molecules [1, 26, 29].  
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Fig. 3- Molecules governing progression through the R point. 
As cells exit mitosis, Rb is unphosphorylated. As cyclin-Cdk 
complexes phosphorylate Rb, the inhibition of E2F transcription 
factors is relaxed and S phase can begin. A variety of molecules 
participate in controlling the promotion or prevention of S phase 
entry. If the p19Arf-p53-p21 and Rb-p16Ink4a pathways that 
restrain E2F release are hyperactivated, a cell may never enter 
into S phase and remain in a senescent state. 
Proteins known as CKIs (cyclin-dependent kinase inhibitors) negatively regulate Cdk 
activity by inhibiting the transfer of phosphorylation groups to target proteins [31, 32]. In 
higher eukaryotes, the two main families of CKIs are the Ink4 family and the CIP/KIP 
family [1, 32]. The members of the Ink4 family get their name because they mainly inhibit 
Cdk4, although they can also inhibit Cdk6 [32]. p16Ink4a, p15Ink4b, p18Ink4c, and p19Ink4d are 
the four Ink proteins that exist in human cells [33-37]. The CIP/KIP family, which includes 
p21Cip1, p27Kip1, and p57Kip2, negatively regulate Cdk1, Cdk2, Cdk4 and Cdk6 [32]. All 
members of the CIP/KIP family contain motifs within the amino-terminal region that 
permit binding to both cyclins as well as Cdks [38-50]. Both families of CKIs can 
effectively stall cell cycle progression by inhibiting Cdk phosphorylation at key transition 
periods during the cell cycle. 
 
In cancer cells, the normal 
requisite for mitogenic 
stimulation for cell cycle reentry 
is ablated. Therefore, a large 
degree of focus in the area of 
tumor biology is on two key 
periods: 1) the transition out of 
G0 and into G1 and 2) the 
commitment to proceed through 
the R point in late G1. Later, the 
molecular mechanism behind the 
G0-G1 transition will be 
discussed when cellular 
senescence is examined in 
greater detail. The key protein 
responsible for the transition 
through the R point in late G1 is 
the tumor suppressor Rb, which 
blocks the entry into S phase [32, 
51-53].  Cells that are in G0 have 
Rb protein (pRb) that is 
essentially unphosphorylated 
(Fig. 3). A small number of 
serine and threonine residues on 
pRb become phosphorylated 
(hypophosphorylated) as cells 
enter into G1, and many 
additional residues are 
phosphorylated 
(hyperphosphorylated) as cells 
transition through the R point 
[54]. Once this critical period has 
been passed, pRb is maintained 
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in a hyperphosphorylated state until the cell exits mitosis at the end of the cell cycle. The 
initiating pRb phosphorylation modifications are dependent on mitogenic stimuli that 
stabilize cyclin D [55]. Without these mitogens, cyclin D levels drastically reduce and all 
phosphate groups on pRb are quickly removed. Without these initial phosphorylation 
modifications of pRb, cyclin E/Cdk2 complexes cannot recognize pRb and pRb 
hyperphosphorylation is prevented. pRb binds to E2F transcription factor family members, 
thereby maintaining them in an inactive state [56].  The activity of these transcription 
factors is absolutely essential for entry into S phase and DNA synthesis [55]. Once pRb is 
hyperphosphorylated, E2F is released and subsequent gene transcription occurs. If cells 
retain pRb in a hyperphosphorylated state after mitosis, mitogens are not required for cell 
division and cell cycle control is ablated, demonstrating that this pathway is critical for 
preventing the formation of cancer. Therefore, it is critical that Cdk activity during this 
period be highly coordinated. Targeting cyclin D and E for destruction is one way to alter 
the activity of Cdk4/6 and Cdk2 in G1. This destruction can proceed through the ubiquitin-
proteasome system, which will be addressed shortly. As an alternative, CKI binding can 
influence the effects of cyclin/Cdk complexes. Early in G1, p16Ink4a blocks the formation of 
cyclin D-Cdk4/6 complexes by reducing Cdk4/6 affinity for cyclin D and also prevents the 
activity of already formed complexes through distortion of the catalytically active Cdk4/6 
site [54]. The induction of p16Ink4a expression proceeds by an as yet to be identified 
mechanism, but relies on Ets1/2 transcription factor activity that may result from several 
different types of stresses [57]. Also, how this inhibitory function of p16Ink4a is quenched to 
allow for cell cycle progression is currently unknown. Interestingly, the CKI’s p21Cip1 and 
p27Kip1 stimulate the formation of cyclin D-Cdk4/6 complexes, while they prevent the 
formation and/or activity of other cyclin-Cdk complexes [58]. Therefore, p21Cip1 and 
p27Kip1 promote pRb hypophosphorylation. However, these proteins prevent the activity of 
cyclin E-Cdk2 complexes and further phosphorylation of pRb. Progression through the R 
point requires a change from cyclin D-Cdk4/6 complex activity to cyclin E-Cdk2 
complexes. How then does a cell transit from active cyclin D-Cdk4/6 complexes into cyclin 
E-Cdk2 complexes? It appears that as cells progress towards the R point, additional active 
cyclin D-Cdk4/6 complexes continue to form, which act to sequester p21Cip1 and p27Kip1 
away from cyclin E-Cdk2 complexes. This allows the liberation of active cyclin E-Cdk2 
complexes, subsequent pRb hyperphosphorylation, and transition through the R point. 
After E2F is released from pRb, this signal is reinforced by additional transcription of 
cyclin E and Cdk2. Whereas SCF ubiquitin ligases control the amounts of p27Kip1 by 
targeting it for destruction, the expression of p21Cip1 is dependent upon p53, a transcription 
factor that functions throughout the cell cycle as a master guardian of several checkpoints 
as well as an executioner of the apoptotic program. 
 
The transcriptional activity of p53 is able to induce a variety of downstream effects, 
including cell-cycle arrest, DNA repair, and apoptosis (Fig. 4) [59]. Under normal 
situations, a cell continuously synthesizes p53 molecules, but because p53 protein is 
degraded very quickly unless it receives post-translational stabilizing modification, a low 
steady-state amount of p53 is present. Once this degradation of p53 is blocked by residue 
modifications, p53 rapidly increases in the cell [60]. This induction is critical for triggering 
the effects mentioned previously. The levels of p53 are increased by DNA damage, 
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Fig. 4- Activating signals and downstream effects of p53. A variety of stress signals result in the rapid 
accumulation of p53, which may result in several different outcomes. Stalls of the cell cycle can occur via 
p21Cip1 transient (temporary) or continuous expression (cellular senescence). DNA repair proteins are 
mobilized in response to active p53, but if they are unable to replace damaged nucleotides, apoptosis may 
ensue. Additionally, p53 functions to block the formation of new blood vessels (angiogenesis) in other 
situations. 
hypoxia, and deregulated signals promoting growth [61].  Mdm2 (Hdm2 in human cells) 
negatively regulates p53 activity by preventing the binding of p53 to target DNA sequences 
(Fig. 3), but Mdm2 also promotes p53 degradation by conjugating ubiquitin molecules to 
p53 (the ubiquitin system will be discussed in detail shortly). Stress or damage results in 
the phosphorylation of p53, making it unable to bind to Mdm2. By preventing this 
association, p53 is able to avoid destruction and the levels rise rapidly. The levels of p53 
can also increase as a result of the actions of the tumor suppressor p19Arf (p14Arf in human 
cells). p19Arf binds to Mdm2 and sequesters it away from p53, thereby preventing 
destruction of p53 by its association with Mdm2 (Fig. 3). Because p21Cip1 functions 
primarily as a cyclin-Cdk inhibitor, stabilization of p53 during nearly every phase of the 
cell cycle results in a stoppage because of subsequent p53-mediated transcription of 
p21Cip1. 
Molecular changes that affect the pRb-p16Ink4a pathway are one of the most common 
features of human cancers [5].  Some ways to perturb this pathway include inactivating Rb 
mutations, high cyclin D activity, and reduced p16Ink4a protein levels. On the other hand, 
the tumor suppressor p53 is probably the single most frequently mutated gene in human 
cancer [5]. Tumor cells cleverly employ both of these alterations to avoid the normal 
regulation of cell growth and induction of apoptosis in order to further propagate 
themselves to allow for tumor progression. However, these cells still require Cdk activity 
to transition through the cell cycle, although the regulation of this activity is highly 
irregular due to aberrancies in Cdk inhibition. An alternative approach to negatively 
regulate Cdk activity relies on the destruction of the associated cyclin by the proteasome, 
resulting in dissociation of cyclin-Cdk complexes. Proteins are targeted for degradation by 
two main families of ubiquitin-conjugating complexes: the APC/C or the SCF. 
 
2.2  THE ANAPHASE PROMOTING COMPLEX (APC/C) 
 
2.2.1  Introduction 
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Along with cyclin/Cdk complex activity, progression through the eukaryotic cell cycle is 
mediated by temporally controlled degradation of cell cycle regulatory proteins by the 
ubiquitin-proteasome system. Proteins degraded by this system are first tagged with a chain 
of at least four lysine 48-linked ubiquitin molecules. The addition of ubiquitin, a highly 
conserved 76-amino acid protein, requires the concerted activation of three enzymes: a 
ubiquitin activating enzyme (E1) [62], a ubiquitin conjugating enzyme (E2) [63], and a 
ubiquitin ligase (E3) [63, 64]. In a reaction that consumes ATP, E1 functions to create a 
high-energy thioester bond between its active-site cysteine and the C-terminal glycine 
residue of ubiquitin, resulting in the activation of ubiquitin [62, 65, 66]. Ubiquitin is then 
transferred to the active-site cysteine residue of the E2 molecule, with a new thioester 
linkage [63]. Lastly, ubiquitin is coupled to a lysine side chain of a target substrate via an 
isopeptide linkage [64]. The final transfer of ubiquitin to a targeted substrate is performed 
by the joint activities of E2 and one of several E3 ligases, which confers substrate 
specificity [64, 67]. Two structurally related multiprotein E3 ligases, the APC/C and the 
Skp1/Cullin/F-box protein (SCF) complexes, drive progression through the eukaryotic cell 
cycle [2, 68-71]. These complexes differ in that the activity of SCF ligases mainly controls 
the transition from G1/S and G2/M [68], while APC/C is primarily required for mitotic 
progression and exit [69, 72-74]. APC/C-mediated ubiquitination of its substrates requires 
one of two coactivators, Cdc20 (cell division cycle 20) or Cdh1/Hct1, and the recruitment 
and transient association of one of two specific E2 enzymes; UbcH10 or UbcH5 [2, 75]. 
APC/C activity needs to be tightly controlled to prevent unscheduled substrate degradation. 
A variety of APC/C inhibitory mechanisms seem to exist to mediate proper substrate 
degradation and control the catalytic activity of APC/C.  
 
2.2.2  Components of vertebrate APC/C 
The initial discovery of APC/C resulted from observations that certain cyclins are 
synchronously degraded as cells pass through mitosis [26]. Cdk1 functions to bring cells 
into mitosis, but its activity needs to be quenched during anaphase and telophase. If Cdk1 
remains in its active state, chromosomes will not decondense, the nuclear envelope will not 
reassemble, and cell division is precluded [2]. Partial inactivation of Cdk1 is also required 
for the separation of sister chromatids during anaphase [76]. The major mechanism for 
Cdk1 inactivation is the destruction of its activating cyclins, cyclin A or B [2]. Cyclin A 
accumulates from late G1 until mitosis, where it is degraded before metaphase, while cyclin 
B is degraded slightly later, in anaphase [77-82]. APC/C, the E3 ligase required to target 
cyclin B for destruction by the ubiquitin-proteasome pathway, was discovered nearly 
simultaneously in Saccharomyces cerevisiae [83], Xenopus eggs and clam oocytes [84, 85].  
 
Subsequent work revealed that the vertebrate APC/C is a multiprotein complex consisting 
of at least 11 core subunits [86-88] (Fig. 5). The largest APC/C subunit is Apc1, which was 
initially discovered in Saccharomyces cerevisiae [89] and Xenopus eggs [90]. It is 
expressed at constant levels throughout the cell cycle but is specifically phosphorylated in 
mitosis [90, 91]. Although the function of Apc1 is largely unclear, it has been suggested 
that this subunit acts either as a scaffolding protein or as a protein required for the 
interaction with polyubiquitinated-proteins [92]. Two APC/C subunits, Apc2 and Apc11, 
contain cullin [86] and RING-H2 finger domains [93], respectively, which are also found 
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Fig. 5- Composition of the mammalian 
anaphase promoting complex/cyclosome 
(APC/C). See text for description of the model. 
in subunits of SCF complexes. The cullin 
domain of Apc2 associates with the RING-
H2 finger domain of Apc11 [94]. The 
RING-H2 finger of Apc11 further mediates 
interaction with the E2 ligases UbcH10 and 
UbcH5 [95]. An unexpected finding was 
that, in vitro, Apc11 and UbcH5 are 
sufficient for polyubiquitination of cyclin B 
[96]. Apc2/Apc11 along with UbcH10 can 
catalyze the ubiquitination of securin and 
cyclin B in vitro [97]. Four subunits of 
APC/C, Apc3/Cdc27, Apc6/Cdc16, Apc7 
and Apc8/Cdc23, all contain a 34-residue 
tetratricopeptide (TPR) motif [98, 99]. This 
motif, which is found in many other 
proteins, is known to mediate protein-
protein interactions in large multi-protein 
complexes [100]. Phosphorylation of Apc3/Cdc27, Apc6/Cdc16, Apc7 and Apc8/Cdc23 
during mitosis is required for APC/C activation and mitotic progression [90, 101]. 
Apc3/Cdc27 and Apc7 have increased affinity for the APC/C coactivator Cdc20 when they 
are phosphorylated [102]. Apc3/Cdc27 and Apc7 bind to Cdc20 and Cdh1 through an 
isoleucine-arginine (IR) dipeptide motif in the C-terminus of the latter proteins [103, 104]. 
In addition, a sequence in the N-terminus of both Cdc20 and Cdh1 called the C-box, is 
necessary for coactivator-APC/C association in yeast [105]. The C-box is not required for 
Cdc20 binding to APC/C in human cells [106] but is thought to play a role in substrate 
recognition [107]. Apc10/Doc1 is a subunit of APC/C that contains a Doc domain that is 
also found in several other proteins of the ubiquitin-proteasome system, including HECT 
and cullin family members [108, 109]. Apc10 is not required for the stable interaction of 
other APC/C subunits, which is somewhat surprising because Apc10 directly interacts with 
Apc3/Cdc27, Apc7, and Apc11 [95, 110]. Mutants of Apc10 are known to prevent 
substrate binding to APC/CCdh1, suggesting that this subunit may play a role in substrate 
recognition [103, 111]. It is not yet clear whether the interaction of the substrate with Cdh1 
and APC/C is directly or indirectly linked to Apc10. Currently, little is known about the 
function of the APC/C subunits Apc4, Apc5, Cdc26, and Apc13. Apc4 and Apc5 bind to 
Apc2 and Apc11, perhaps mediating the interaction of these proteins with the TPR-motif-
containing APC/C subunits [104]. Cdc26 plays a role in maintaining the structure of 
APC/C [86, 87, 112]. Apc13, which binds to Apc5 and Apc8/Cdc23 [88], presumably plays 
a more critical role in meiosis than in mitosis, although its exact function is unclear [113]. 
 
The fully assembled vertebrate APC/C consists of two large domains [114-116]. These 
domains, referred to as the “platform” and the “arc lamp”, have a large amount of 
flexibility relative to each other [117]. When APC/C associates with the cofactor Cdh1, a 
conformational change in the relative positions of the “platform” and “arc lamp” occurs, 
perhaps mediating the activation of APC/C [116]. It is not yet known where Cdc20 binds to 
APC/C or if this binding results in a similar change of APC/C conformation. 
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Disruption of APC/C subunits by genetic manipulation leads to early lethality in every 
species examined thus far, from simple organisms like fungi to advanced vertebrates like 
mice [83, 118-120]. It is commonly believed that this lethality is due to the accumulation of 
securin and mitotic cyclins which inhibits chromosome segregation and mitotic exit [2]. 
However, APC/C is responsible for degradation of several other proteins as well, and it is 
entirely possible that overabundance of another substrate may result in cell death [117]. 
Therefore, it is critical that the activity of this complex be tightly regulated to prevent 
premature activation, yet also be flexible enough to allow for efficient transfer of ubiquitin 
when required.  
 
2.2.3  Formation of APC/C and substrate recognition 
Phosphorylation of APC/C subunits regulates both the function and the assembly of the 
mature complex. Three kinases mediate APC/C subunit phosphorylation: Protein Kinase A 
(PKA), Polo like kinase 1 (Plk1), and cyclin B/Cdk1 [121-124]. Phosphorylation of 
Apc3/Cdc27, Apc6/Cdc16 and Apc8/Cdc23 by cyclin B/Cdk1, leads to binding of Cdc20 
to APC/C [84, 121, 124, 125]. Plk1 also promotes APC/C-mediated ubiquitination, but 
only in synergy with cyclin B/Cdk1 [121, 122]. In contrast to the activation of APC/C by 
these two kinases, PKA phosphorylation of APC/C inhibits the destruction of cyclin B, 
even when all activating cofactors are present [124]. It remains to be established which 
phosphatase functions to remove these inhibitory modifications. 
 
The coactivators Cdc20 and Cdh1 are only transiently associated with APC/C. Substrates 
that have a destruction box (D box) or a KEN box are recognized and ubiquitinated by the 
APC/C [126, 127]. D box recognition elements, with the consensus amino acid sequence of 
RXXLXXXN, are found in several proteins, including mitotic cyclins, and are essential for 
ubiquitin-mediated destruction [127]. The KEN box, which contains a consensus KEN 
amino acid sequence, is found in several APC/C substrates and is preferentially, but not 
exclusively, recognized by APC/CCdh1 [126]. Most substrates only bind to APC/C when it 
is activated by Cdc20 or Cdh1 [114]. Binding of Cdc20 to APC/C is tightly regulated to 
prevent premature APC/C-mediated ubiquitination. Regulation of Cdc20 occurs at various 
levels, with the protein being transcribed and translated during S and G2 phases, and 
phosphorylation occurring in a cell cycle dependent fashion [128-130]. Phosphorylation of 
Cdc20 does not induce the activation of APC/C, but results in coactivator recognition by 
components of the spindle assembly checkpoint in mitosis, resulting in APC/C inhibition 
and anaphase prevention [131]. This regulation of APC/C activity is critical to prevent the 
acquisition of chromosomal aberrations and is discussed in detail below. 
 
2.2.4  Mitotic substrates of APC/C 
Current models propose that APC/CCdc20 is active during the early stages of mitosis, 
whereas APC/CCdh1 is active in late mitosis and G1 (Table 1). In early mitosis, Cdh1 is 
phosphorylated by cyclin B/Cdk1, which precludes its association with APC/C [132-135]. 
Cyclin/Cdk1 activity is required to phosphorylate Cdc20, making the APCCdc20 complex 
completely active [136]. Only after Cdk1 has been inactivated, by APC/CCdc20-mediated 
destruction of cyclin A and B, inhibitory phosphates can be removed from Cdh1 by Cdc14, 
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       Table 1- Mitotic substrates of APC/C. 
thereby allowing this coactivator to associate with APC/C [132, 137]. However, recent 
findings, which will be discussed later, challenge this view. A summary of known mitotic 
substrates of APC/C mediated ubiquitination can be found in Table 1. 
 
Various mechanisms control the catalytic activity of APC/C. Early mitotic inhibitor 1 
(Emi1) prevents premature activation of APC/C by interacting with newly synthesized 
Cdc20 [138-140]. In prophase, Plk1 phosphorylates Emi1. This modification targets Emi1 
for destruction by the SCFβTrCP E3 ligase [141], which, in turn, leads to formation of active 
APC/CCdc20. Overexpression of Emi1 in cells lacking p53 has been shown to promote 
proliferation, tetraploidy and chromosomal instability [142], underscoring that Emi1 is a 
key mitotic regulator. A recent study suggests that following the destruction of Emi1 in 
prophase, Cdc20 continues to be inhibited through prometaphase by the tumor suppressor 
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protein Ras association domain family 1 (Rassf1A) [143]. At the end of prometaphase, 
when this inhibition ceases, APC/CCdc20 becomes active and begins to ubiquitinate Nek2a 
and cyclin A, resulting in the complete destruction of these substrates in metaphase (Table 
1) [82, 144, 145]. Nek2a binds to APC/C directly, without any need for adapter proteins or 
coactivator molecules [145]. Its subsequent destruction can then ensue upon APC/C 
activation by coactivator binding. Perhaps cyclin A is degraded in a similar fashion, but 
this remains to be confirmed.  
 
In order for a cell to transit from metaphase to anaphase, several key substrates of APC/C 
need to be degraded, including cyclin B and securin (Table 1) [2, 85, 146-150]. Anaphase 
onset is marked by the separation of sister chromatids, which are held together by a large 
multi-protein complex called cohesin [151, 152]. Separase is the enzyme that mediates 
cohesin cleavage [151]. Until the metaphase to anaphase transition, securin binding and 
cyclin B/Cdk1-mediated phosphorylation inhibit the enzymatic activity of separase, thereby 
preventing premature sister chromatid separation (PMSCS), a hallmark of premature 
APC/C activation [76, 153, 154]. The phosphatase responsible for the removal of the 
inhibitory modification of separase is currently unknown [76]. A recent study has 
demonstrated that cyclin B binding to separase alone, without a requirement for cyclin 
B/Cdk1-mediated phosphorylation, is sufficient to inhibit separase activity [155]. The view 
that APC/CCdc20 regulates degradation of both cyclin B and securin at the 
metaphase/anaphase transition, has been challenged by gene knockout studies showing that 
premature activation of APC/CCdc20 leads to unscheduled degradation of cyclin B, but not 
securin [146]. Premature activation of APC/CCdh1, on the other hand, leads to the 
precocious degradation of securin, but not cyclin B, in vivo [146, 156]. The latter finding 
has established a critical role for the activity of APC/CCdh1 in mitosis much earlier than 
originally thought.  
 
In addition to securin and cyclin B, several other proteins need to be degraded to allow for 
anaphase entry and progression. Xenopus Xkid is implicated in generating the polar 
ejection force that makes the chromosomes align during metaphase [157, 158]. In order for 
chromosomes to migrate to the poles in anaphase, Xkid needs to be degraded. Both 
APC/CCdc20 and APC/CCdh1 have been shown to ubiquitinate Xkid in vitro [159]. The motor 
proteins Kip1 and Cin8 are degraded during anaphase by APC/CCdc20 and APC/CCdh1, 
respectively, to allow polar movement of chromosomes [160, 161]. Another protein whose 
degradation is required for progression through anaphase is Prc1. This protein associates 
with the spindle midzone and is subjected to ubiquitination by APC/CCdh1 [162, 163]. 
APC/CCdh1 also degrades the microtubule-associated protein Tpx2. Its degradation starts in 
anaphase and continues through cytokinesis [164]. Geminin, a protein that inhibits DNA 
replication, is targeted by APC/C beginning at metaphase and continuing until the cell’s 
exit from mitosis [165]. It is currently unclear which APC/C coactivator drives geminin 
destruction. Complete ablation of geminin results in endoreduplication [166], 
demonstrating that APC/C-mediated destruction of this protein requires strict temporal 
regulation. The mitotic kinases Plk1 [167] and Aurora B [168] are also destroyed late in 
mitosis. Their destruction by APC/CCdh1 allows for entry into G1. Anillin, which controls 
the spatial contractility of myosin at the cleavage furrow during cytokinesis, is targeted by 
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APC/CCdh1 for destruction late in cytokinesis and into G1 [169]. However, this destruction 
is not required for mitotic exit in mammalian cells. The activity of Cdh1 bound APC/C 
continues through G1, where it regulates the destruction of Cdc20 [126, 170, 171], Aurora 
A, and mitotic cyclins to prevent the re-accumulation of these proteins [172-174]. Control 
of APC/C activity during mitosis is controlled by a variety of inhibitory mechanisms, most 
notable the spindle assembly checkpoint. 
 
2.3  CONTROLLING APC/C FUNCTION DURING MITOSIS 
 
2.3.1  Introduction 
The catalytic activity of APC/C during mitosis is mediated by several surveillance 
mechanisms, most notable the spindle assembly checkpoint. This checkpoint, which is 
often referred to simply as the mitotic checkpoint, is a molecular system that ensures 
accurate segregation of mitotic chromosomes by delaying anaphase onset until each 
kinetochore has properly attached to the mitotic spindle [175-177]. The kinetochore is a 
highly specialized region of mitotic chromosomes, corresponding to the centromere [178]. 
Centromeric regions are extremely complex; in that they have very large numbers of 
tandem repeats existing in arrays [179, 180]. Kinetochores consist of an inner and outer 
region. A large multiprotein complex can be found at the inner kinetochore. This complex 
appears as a narrow band of dense chromatin under electron microscopy and can be 
detected throughout the cell cycle [181, 182]. The outer kinetochore contains many of the 
proteins responsible for microtubule binding and signal transduction [181]. Trapping of 
microtubules by the kinetochore is an essential process, yet this capture is relatively fluid, 
with the microtubules able to grow and shrink at the site of attachment to the kinetochore 
[182]. The kinetochore complex is also highly dynamic, allowing some of its proteins to 
leave upon attachment of microtubules or during progression through mitosis [182]. 
Kinetochores that are not yet attached to mitotic microtubules and chromosome pairs that 
lack tension across sister chromatids generated by the spindle poles activate the spindle 
assembly checkpoint [183-187].  
 
2.3.2     The spindle assembly checkpoint 
Several proteins participate in the spindle assembly checkpoint-signaling pathway [181, 
184]. The established view is that early in mitosis, various mitotic checkpoint proteins, 
including Bub1, BubR1, Bub3, Mad1, and Mad2 bind to the outer region of kinetochores 
that lack attachment or tension to generate a “stop anaphase” signal that diffuses into the 
mitotic cytosol [72, 184, 185, 188-198] (Fig. 6A). This signal is believed to consist of 
complexes of Bub3, BubR1 and Mad2, which bind and inhibit APC/CCdc20 [2, 95, 199, 
200]. As each pair of sister kinetochores attaches to microtubules, and microtubule motors 
generate tension that stretches them, production of inhibitory “stop anaphase” signals at 
those kinetochores quenches. Silencing of the “stop anaphase” signal only occurs after the 
final kinetochore has been captured by spindle microtubules [176, 190, 201], which 
triggers the release of inhibitory mitotic checkpoint protein complexes from APC/CCdc20 
(Fig. 6B). This then allows for APC/CCdc20-mediated destruction of cyclin B and securin 
[72, 73, 189, 192, 202, 203]. Separase, which in mammalian cells is inhibited through its 
association with securin and by cyclin B/Cdk1-mediated phosphorylation, subsequently 
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triggers sister chromatid disjunction by cleavage of the cohesin subunit Scc1 [151, 204]. 
This allows cells to progress into anaphase (Fig. 6C).  
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2.3.3  Other regulatory mechanisms of APC/C activity during mitosis 
Recent work involving the nuclear transport factors Nup98 and Rae1 has challenged 
several aspects of the above model of spindle assembly checkpoint function [146]. Mutant 
mice that express low levels of both Nup98 and Rae1 exhibit PMSCS and massive 
aneuploidy. In cells from these mice, securin undergoes ubiquitin-mediated destruction in 
prometaphase instead of at anaphase onset. On the other hand, the timing of cyclin B 
destruction is normal in these cells. In prometaphase, Rae1 and Nup98 were observed to 
interact specifically with APC/CCdh1 to prevent degradation of securin, but not APC/CCdc20 
(Fig. 7A), which was surprising as previous studies suggested that the formation of 
APC/CCdh1 in early mitosis is inhibited through phosphorylation of Cdh1. However, this 
mechanism does not completely prevent APC/CCdh1 formation in early mitosis. In fact, 
comparative coimmunoprecipitation experiments suggest that there are very similar 
amounts of APC/CCdc20 and APC/CCdh1 in early mitosis [156]. Dissociation of Rae1 and 
Nup98 from APC/CCdh1 coincides with the release of BubR1 from APC/CCdc20 [146]. 
Because the release of BubR1, and its coinhibitors Bub3 and Mad2, occurs at the 
metaphase/anaphase transition to activate APC/CCdc20 and drive cells into anaphase, it is 
likely that the dissociation of Rae1 and Nup98 from APC/CCdh1 also occurs at this mitotic 
stage and for the same purpose. If APC/CCdc20 promotes anaphase through ubiquitination of 
both cyclin B and securin, one would expect to observe premature degradation of both of 
these proteins in cells in which BubR1 is deficient. However, only cyclin B is prematurely 
degraded in such cells, suggesting that Cdc20 is the primary coactivator for degradation of 
cyclin B, but not for degradation of securin in vivo. Conversely, APC/CCdh1 activated by 
release of Rae1 and Nup98 might have a more important role in the destruction of securin 
(Fig. 7B, C). It is currently not understood how the Rae1-Nup98 complex is targeted to 
Cdh1 in response to lack of attachment at kinetochores and how it senses kinetochore 
capture to release its inhibition of APC/CCdh1. Rae1 is known to form a complex with Bub1 
and localize to unattached kinetochores [193, 196]. One possibility is that these Bub1-Rae1 
complexes regulate Nup98-Rae1 binding to APC/CCdh1, perhaps in much the same way as 
other kinetochore-associated mitotic checkpoint proteins promote binding of Bub3-BubR1-
Mad2 complexes to APC/CCdc20. 
 
Additional means of regulating the ubiquitin ligase activity of APC/C during mitosis are 
beginning to be elucidated. A complex of CBP and p300, two transcription factors, is 
essential for APC/C activity in mitosis [205, 206]. Through reciprocal immunoprecipitation 
assays, it has been shown that CBP/p300 interacts with three structural components of 
APC/C, in addition to the coactivators Cdc20 and Cdh1 [206]. Furthermore, CBP 
colocalizes with APC/C and siRNA-mediated depletion of CBP leads to reduced APC/C 
E3 ligase activity and the accumulation of cyclin B and Plk1 [206]. Together these findings 
implicate CBP/p300 in activation of both coactivator bound forms of APC/C during 
mitosis. This regulation may be through CBP/p300-mediated acetylation of APC/C 
subunits and/or the coactivators Cdh1 and Cdc20, although the details are not clearly 
established currently. It will be interesting to examine in future experiments whether the 
actions of CBP/p300 in mitosis are regulated by the spindle assembly checkpoint. The 
implication of Rae1-Nup98 and CBP/p300 complexes in mitotic regulation of APC/C 
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highlights that controlling APC/C activity in mitosis is far more complex than was once 
thought.  
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2.3.4  Summary 
An emerging theme in the regulation of APC/C-mediated degradation of substrates in 
mitosis is that three key components associate with APC/C (Fig. 8). These three 
components are: (1) APC/C coactivators; (2) inhibitory protein complexes that prevent 
unscheduled APC/C-mediated ubiquitination; and (3) the substrate that needs to be 
degraded. In this way, APC/C is loaded with the target substrate before the transfer of 
ubiquitin takes place through the association of an E2 enzyme. Once the inhibitory 
complex is removed from APC/C, swift degradation of bound substrates can ensue because 
the APC/C is primed for destruction by having the coactivator and the substrate existing in 
a large complex.  
 
The first example that supports this hypothesis occurs in prophase. Two early mitotic 
substrates of APC/C are Nek2a and cyclin A. To prevent the unscheduled destruction of 
these proteins, Emi1 binds to both Cdc20 and Cdh1 before these two coactivators can 
associate with APC/C [138, 139]. Both Cdc20-Emi1 and Cdh1-Emi1 complexes can 
associate in vitro with APC/C, but only Cdc20-Emi1 loads onto APC/C in vivo in early 
mitosis [139]. Emi1 inhibits APC/C until Plk1 phosphorylates Emi1 and allows it to be 
recognized and ubiquitinated by the SCFβTrCP ubiquitin ligase [141]. Degradation of Emi1 
allows Cdc20 activation of preformed APC/C-Nek2a complexes, which in turn leads to 
prompt destruction of Nek2a [139, 145]. It is therefore possible that Nek2a binds to APC/C 
while Cdc20-Emi1 complexes are forming and loaded onto APC/C (Fig. 8).  
 
The second example that supports our model occurs during prometaphase. The well-
established MCC inhibitory complex consists of Mad2, Bub3, and BubR1 bound to Cdc20. 
Association of this complex to APC/CCdc20 inhibits the ligase activity until the spindle 
checkpoint is satisfied. Once the checkpoint is silenced, the inhibitory MCC complex 
dissociates from APC/CCdc20, which results in APC/C activation and swift destruction of 
cyclin B and potentially securin. Importantly, cyclin B already associates with APC/C in 
prometaphase even though its destruction takes place much later at the metaphase to 
anaphase transition [156]. Thus, both cyclin B and the MCC may bind to APC/CCdc20 
similarly to the way Nek2A and Emi1 associate with APC/CCdc20 (Fig. 8). 
 
The third example that supports our model also occurs during prometaphase. The Rae1-
Nup98 inhibitory complex binds to securin-bound APC/CCdh1 complexes [156]. The rapid 
degradation of securin occurs at a similar rate to cyclin B destruction when the spindle 
assembly checkpoint is satisfied. Release of Rae1-Nup98 and MCC inhibitory complexes 
occurs at nearly the same rate, but the mechanism behind the release of Rae1-Nup98 is not 
known. The rapid synchronous nature of cyclin B and securin degradation suggests that 
APC/C is primed for the destruction of these two key mitotic regulators. Having the 
substrate bound to inactivated APC/C could explain this precise regulation. 
  
Currently, the events of late mitosis are not well understood at the mechanistic level. 
Following the metaphase-anaphase transition, ubiquitin-mediated destruction of substrates 
primarily occurs through APC/CCdh1, but it is not known if other inhibitory complexes 
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Fig. 8- Inhibitory mechanisms of APC/C catalytic activity during mitosis. In early mitosis, Emi1 regulates 
the activity of APC/CCdc20. The well-established MCC and the newly found Nup98-Rae1 complex inhibit the 
catalytic activity of APC/C during prometaphase, thereby preventing substrate degradation. In vitro evidence 
suggests that APC/CCdc20 also regulates the destruction of securin, but it is not known if MCC also binds to 
this pool of APC/C. Perhaps additional inhibitory complexes are found later in mitosis to prevent the 
unscheduled degradation of other key mitotic regulator proteins. The existence of inhibitory complexes may 
explain how the cell discriminates between early and late mitotic APC/C substrates. 
prevent the premature degradation of substrates during late mitosis. Perhaps additional 
complexes associate with APC/C to mediate the destruction of late mitotic substrates, 
however it is currently an unexplored topic. 
 
2.4  FUNCTIONAL ANALYSES OF MITOTIC CHECKPOINT PROTEINS 
 
2.4.1  Introduction 
Many spindle assembly checkpoint genes have now been disrupted in the mouse, the 
results of which are summarized in Table 2. Most of them belong to either the Bub 
(Budding uninhibited by benomyl) or the Mad (Mitotic arrest deficient) gene family. 
Members of these families were originally identified in yeast, where they are dispensable 
for survival [207]. It was therefore surprising that homozygous knockout mice all died very 
early in development. On the other hand, mice that are heterozygous null for these genes 
are born alive and seem to exhibit no overt phenotypes. Thus, the challenge for studying 
the function of individual mitotic checkpoint genes in the mouse is to disrupt their function 
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Table key:  – = not relevant; ND = not determined; (1) = chromosome breaks and gaps were also observed at high 
frequency (2) = 50% decrease in overall tumor burden in GI tract but increased number of tumors in the colon; (3) 
= small increase that was not significant; (4) = decreased number of tumors compared to wild-type; (5) = 
increased in lung and spleen, decreased in liver. 
 
significantly but not so severely that the embryo dies. This goal can be achieved through 
the use of hypomorphic alleles that express only a small fraction of normal protein levels. 
Proper spindle assembly checkpoint function and timely activation of APC/C and 
destruction of its substrates are essential for accurate chromosome segregation. Aberrant 
checkpoint signaling leads to defects in inhibition of APC/C activity, resulting in untimely 
entry into anaphase and a high risk of segregation defects (Table 2). PMSCS, which can 
ultimately contribute to chromosomal instability, is caused by separation of duplicated 
chromatids before entry into anaphase and is seen in several spindle assembly checkpoint 
mutant mice [208]. Kinetochores that lack microtubule attachment and/or tension but fail to 
activate the spindle assembly checkpoint and inhibit APC/C activity will produce lagging 
chromosomes. Additionally, merotelic kinetochore attachment causes lagging 
chromosomes [209]. During anaphase, a lagging chromosome does not move towards the 
spindle poles along with other chromosomes. It is distributed randomly in one of the two 
daughter cells, which may potentially result in a gain or loss of a whole chromosome. 
Other missegregation defects, including anaphase bridges may also be present when the 
spindle checkpoint is defective [208]. Here we will focus on several key players in the 
spindle checkpoint and the consequences of these genes being disrupted in mice. 
 
2.4.2  Mad2 and Mad1 
Information obtained from crystal structure studies demonstrates that Mad2 exists in two 
natively folded states. One is a less stable monomeric form with what is termed native fold 
1 (N1-Mad2) and the other is a more stable homodimeric form with native fold 2 (N2-
Mad2). Mad2 is able to switch between these two conformations, but this spontaneous 
process occurs very slowly [210]. The homodimer of N2-Mad2 is able to inhibit the 
activity of APC/CCdc20, whereas N1-Mad2 is unable to interact with Cdc20 [210]. 
Furthermore, a heterodimer of N1-Mad2 and N2-Mad2 is unable to inhibit APC/C activity 
as well, demonstrating that either conformation of N1-Mad2 into N2-Mad2 or replacement 
of N1-Mad2 in heterodimers is required for Cdc20 binding and subsequent inhibition of 
APC/C-mediated ubiquitination. Mutants of Cdc20 that are unable to bind to Mad2 
undergo mitosis independently of Mad2, demonstrating how critical this inhibition by 
Mad2 is for mitotic progression [225]. Along with being distributed in the mitotic cytosol 
in early mitosis, Mad2 localizes to unattached kinetochores [226, 227]. This localization is 
often used as a cellular marker to demonstrate that the spindle assembly checkpoint is 
engaged. The recruitment of Mad2 to kinetochores is accomplished via its binding to Mad1 
[228]. Mad1 stimulates the transition of Mad2 to the N2-Mad2 conformation, resulting in 
activation of Mad2 [210]. This conformational change causes N2-Mad2 to dissociate from 
Mad1, and is subsequently replaced by free Mad2 [131, 229]. Mad2 interacts with BubR1 
and Bub3 in the mitotic cytosol to inhibit APC/CCdc20 activity as part of the mitotic 
checkpoint complex or MCC. Upon microtubule attachment to kinetochores, Mad2-Mad1 
complexes leave the kinetochore and conformational changes of Mad2 are inhibited [230]. 
Multiple phosphorylation sites exist on Mad2, but only non-phosphorylated Mad2 binds to 
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Cdc20 and Mad1 [231]. Transformation/transcription domain-associated protein TRRAP, 
which has chromatin-remodeling histone-acetlytransferase activity (HAT), specifically 
regulates the expression of both Mad1 and Mad2 [232]. Members of the E2F family of 
transcription factors also mediate Mad2 transcription. Mad2 also plays a role in reorienting 
chromosomes that are incorrectly attached to the spindle during the process of meiosis 
[233], but it is unknown if Mad2 does this during mitosis as well. A Mad2 related protein, 
Mad2L2, inhibits APC/CCdh1 in much the same way as Mad2 does for APC/CCdc20 [107]. 
 
Mad2 and Mad1 Mouse Studies. Mad2 was the first published mitotic checkpoint gene to 
be knocked out in mice [211]. Homozygous knockout mice die shortly after implantation 
around embryonic day E6.5. This lethality is coupled with massive chromosome 
missegregation and apoptosis [211]. When challenged with nocodazole, a microtubule de-
polymerizing agent that triggers the activation of the spindle checkpoint, cells from Mad2 
null embryos lack the ability to arrest in prometaphase. [211]. Cells that were post-mitotic 
however do not require Mad2 to survive. Studies on mouse embryonic fibroblasts (MEFs) 
suggest that the fidelity of the spindle assembly checkpoint is already affected when a 
single Mad2 gene copy is lacking, as a substantial proportion of Mad2 heterozygous MEFs 
develop aneuploidy and show PMSCS [234]. Mad2 haplo-insufficient mice seem to have a 
normal lifespan without any overt phenotypes. At about 18 months, the incidence of 
papillary lung adenocarcinomas, a usually very rare tumor, is significantly higher in Mad2 
heterozygous mice than in wild-type mice [234]. Being as these tumors developed very late 
in life, it appears that cooperative mutations of tumor suppressors or oncogenes are 
required for transformation of checkpoint defective cells [234]. 
 
The expression of Mad2 is elevated in cells that lack pRb due to increased E2F 
transcription factor activity [235]. Mad2 is a direct E2F target, and the overexpression of 
these two proteins occurs in several tumor types [235]. This overexpression of Mad2 
catalyzes the development of aneuploidy, demonstrating that the aberrant expression of this 
gene at abnormal times during the cell cycle may potentially contribute to the process of 
tumorigenesis. Transgenic Mad2 expressing mice have been reported very recently [214]. 
High levels of Mad2 in MEFs results in an initial reduction in growth due to accumulation 
of cell in mitosis, which similar to what is seen in yeast [225, 236]. However, some of 
these MEFs escape mitosis without segregation of DNA, resulting in the generation of 
tetraploid cells. A wide range of mitotic defects are detectable in these MEFs, 
demonstrating that the aberrant overexpression of Mad2 results in several features of 
chromosomal instability. Mice overexpressing Mad2 are susceptible to several tumor types, 
including lung adenomas, hepatomas, intestinal tumors and lymphomas [214]. 
Interestingly, tumor maintenance does not require the continual overexpression of Mad2. 
This study demonstrates that the transient overexpression of Mad2 and subsequent 
chromosome instability can be an important stimulus in the initiation and progression of 
certain tumor types. 
 
Mad1 has recently been ablated in the mouse [215]. Homozygous null mice die during 
embryogenesis, although it has not yet been determined at what stage of development 
Mad1 is essential. Mad1 heterozygous mice are viable and indistinguishable from wild-
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type littermates. Mad1 heterozygous MEFs have increased incidence of lagging 
chromosomes and bridging, two defects that are also seen at increased rates in Mad2 
heterozygous null MEFs [215]. The spontaneous tumor incidence of 18-month-old Mad1 
heterozygous mice was about two-fold higher than in age-matched wild-type controls, 
indicating the Mad1 insufficiency promotes the development of spontaneous tumors, just 
like Mad2. Hemangiosarcomas and lung adenomas/adenocarcinomas were among the most 
frequently observed tumors in Mad1 haploinsufficient mice. It remains to be established 
whether Mad1 mutant mice have increased susceptibility to carcinogens.  About 40% of 
nude mice injected with Mad1 heterozygous MEFs develop tumors within 6-10 weeks, 
compared to 0% for control MEFs, further confirming that partial loss of Mad1 increases 
the risk of neoplastic transformation. 
 
2.4.3  Bub3 
Bub3 is a dispensable protein in yeast that is essential for vertebrate embryogenesis [196, 
221, 237]. Bub3 binds to BubR1 and Bub1 through a Gle2-binding sequence (GLEBS 
motif) and this binding is required for kinetochore localization of these two proteins [238]. 
When chromosomes are aligned properly at the metaphase plate, Bub3 is undetectable at 
the kinetochore. Lagging chromosomes that have not attached properly to the mitotic 
spindle exhibit high levels of Bub3 at the kinetochore, implicating this protein as a sensor 
of microtubule attachment [239]. The MCC inhibitory complex contains Bub3, BubR1, 
Mad2, and Cdc20 to specifically inhibit APC/CCdc20 in the mitotic cytotsol. In addition to 
its role during mitosis, Bub3, like Cdc20, also functions as transcriptional regulator during 
interphase by associating with histone deacetylases [240]. 
 
Bub3 Mouse Studies. Similar to Mad2 knockouts, complete ablation of Bub3 causes 
mouse embryos to die shortly after implantation in the uterus [196, 221]. Cells from these 
embryos show features of mitotic disarray, including lagging chromosomes and chromatin 
bridging. Micronuclei also develop due to lagging chromosomes that do not congregate 
with the rest of the DNA in the newly formed daughter cell nucleus [221]. In the presence 
of nocodazole, Bub3 null cells fail to induce a sustained mitotic arrest [221], confirming 
that their spindle assembly checkpoint is impaired. Heterozygous loss of Bub3 results in a 
partial loss of spindle assembly checkpoint function, coupled with increased chromosome 
missegregation and development of moderate aneuploidy in both MEFs and splenocytes 
[196]. When challenged with the carcinogen DMBA, Bub3 haplo-insufficient mice develop 
lung adenocarcinomas at a slightly higher incidence than control animals, although the 
increase is not statistically significant [196]. Bub3 haplo-insufficient mice are not 
predisposed to spontaneous tumorigenesis, and furthermore, the spectrum of tumor types 
found in these mice is similar to that of wild-type mice [213, 241]. p53 or Rb1 
heterozygous knockout mice bred onto a Bub3 heterozygous background have similar 
tumor spectrums and tumor incidences as their counterparts that have two intact Bub3 
alleles [241]. Thus, despite accumulation of aneuploid cells, Bub3 haplo-insufficient mice 
do not seem to be prone to spontaneous tumors or to developing tumors on a predisposed 
genetic background.  
 
  39 
2.4.4  Rae1 
Rae1, also called Gle2 or mrnp41, is a transport factor that mediates nuclear export of 
mRNA through nuclear pores during interphase. Rae1 and Bub3 are WD repeat-containing 
proteins that share remarkable sequence similarity both inside and outside of these repeats 
[238, 242]. The finding that Rae1 binds to the GLEBS motif of Bub1 at kinetochores 
during mitosis suggested a mitotic function for this protein [193]. Additionally, the 
nucleoporin Nup98 contains a GLEBS motif that interacts with Rae1 throughout the cell 
cycle [243], and this complex was found to be important for regulating the activity of 
APC/CCdh1 as mentioned previously [146, 156]. Additionally, Rae1 binds to NuMA 
(Nuclear Mitotic Apparatus) during mitosis, which is a required interaction for normal 
mitotic spindle formation [244, 245]. 
 
Rae1 Mouse Studies. Rae1 null mice exhibit a phenotype that is reminiscent of Bub3 null 
mice, strengthening the idea that these two proteins are highly related [196]. Furthermore, 
when challenged with nocodazole, Rae1 haplo-insufficient MEFs fail to arrest in 
prometaphase, just like Bub3 heterozygous MEFs [196]. These findings, combined with the 
observation that Rae1 heterozygous mice and MEFs have increased aneuploidy, indicates 
that Rae1 is a genuine and essential component of the spindle assembly checkpoint [196]. 
Importantly, the lung tumor incidence and burden are both significantly higher in Rae1 
heterozygous mice than in wild-type mice when challenged with DMBA [196], although 
these mice are not prone to spontaneous tumor formation [213]. 
 
Mice that are heterozygous for both Bub3 and Rae1 accumulate many more aneuploid cells 
than the corresponding single heterozygotes, yet remain viable [196]. PMSCS is also much 
higher in double mutant mice than in single mutant mice, demonstrating that Rae1 and 
Bub3 are related proteins with essential, and cooperating roles in the mitotic checkpoint. In 
carcinogen treated mice, the lung tumor incidence and tumor number of double 
heterozygous mice is very similar to Rae1 single heterozygous animals. Since the 
aneuploidy is 3-fold higher in the double heterozygotes, it seems that the aneuploidy might 
not be the primary cause of increased carcinogen-induced tumorigenesis in mitotic 
checkpoint defective animals [196]. Also, these mice, despite massive aneuploidy, are not 
prone to developing spontaneous tumors [213]. However, mice that are double 
haploinsufficient for Bub3 and Rae1 exhibit several aging-associated phenotypes 
significantly earlier than wild-type mice (Chapter 6) [213]. These results are discussed in 
more detail later. 
 
Mice that are haplo-insufficient for Nup98 and Rae1 have substantial PMSCS and 
aneuploidy [146]. Concordantly, these mice are predisposed to carcinogen induced tumor 
formation (Chapter 7) [156]. However, as is the case for Bub3/Rae1 double haplo-
insufficient animals, the spontaneous tumor incidence remains unchanged in these animals 
[156]. This model was extremely useful however, as cells from these animals were used to 
identify a novel regulatory complex of APC/C activity during mitosis [146, 156]. 
 
2.4.5  BubR1 
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The spindle checkpoint protein BubR1 is the mammalian homolog of yeast Mad3 [238]. 
Protein levels of BubR1 are cyclical, such that it is extremely low in G1 until late G2, but 
rises markedly at mitosis [246]. BubR1 contains a GLEBS motif that results in constitutive 
binding of BubR1 to Bub3 [193]. This binding is required for recruitment of BubR1 to 
kinetochores during prometaphase, as mutations in the GLEBS motif ablate the binding 
and localization of BubR1 [238]. BubR1 mediated inhibition of APC/C does not require the 
binding of Bub3 however [95], as Cdc20 can be bound directly by BubR1. Cenp-E, a 
mitotic motor protein, binds to BubR1, and maintains stable microtubule-kinetochore 
interactions, which are required for proper checkpoint signaling [247]. BubR1 contains a 
kinase domain, which yeast Mad3 does not, and this kinase is essential for other spindle 
checkpoint functions other than APC/C inhibition [201]. The kinase activity of BubR1, 
both for self-phosphorylation and for non-specific targets, is stimulated upon the binding of 
Cenp-E [201]. Interestingly, p53 can control the transcription of BubR1 [248], although 
other proteins can compensate for p53 loss.  
 
BubR1 Mouse Studies. Two laboratories have generated mice that lack BubR1. Wang and 
colleagues disrupted the BubR1 gene through retroviral insertion mutagenesis. They show 
that complete ablation of BubR1 results in embryonic lethality with massive apoptosis 
[249]. MEFs that are heterozygous for the retrovirally inactivated BubR1 allele express 
about 25% of normal protein levels [219, 249]. These MEFs form micronuclei at a high 
frequency and have the tendency to become hypo- or hyperdiploid [250]. When challenged 
with nocodazole, these MEFs seem unable to induce a sustained arrest in prometaphase, 
coupled with impaired BubR1 phosphorylation, premature securin and cyclin B 
degradation, and early mitotic exit [219, 249, 250]. Mice that are heterozygous for 
retrovirally inactivated BubR1 exhibit profound splenomegaly, a condition where the 
spleen is much larger than in normal mice [249]. These mice further show an increased 
susceptibility to azoxymethane (AOM), a carcinogen that primarily induces intestinal 
tumors in mice. Surprisingly, BubR1 heterozygotes not only developed intestinal tumors at 
a higher incidence than wild-type mice, but also lung tumors [219]. 
 
Mice carrying the Adenomatous polyposis coli (Apc) Min allele typically develop 
numerous tumors in the small intestine and an occasional tumor in the colon. When one 
BubR1 gene copy is inactivated in these mice, the total number of tumors declines 
significantly due to a dramatic drop in the average number of tumors in the small intestine 
[250]. Double mutant mice develop 10-fold more colonic polyps than mice that only carry 
the Apcmin mutation [250], although the contribution of colonic polyps to the overall tumor 
burden remains low. The exact reason for this difference remains unclear. MEFs of double 
compound mutant mice exhibit increased proliferation potential along with increased 
genetic instability [250]. These results suggest that BubR1 and Apc functionally interact in 
regulating the transition of metaphase to anaphase, and deregulation of this may play a role 
in genomic instability development and the process of colon carcinogenesis. 
 
Recently, we have reported the generation of a series of mice in which the expression of 
BubR1 is reduced in a graded fashion from normal levels to zero by the use of wild-type, 
knockout and hypomorphic alleles (Chapter 3) [218]. Hypomorphic alleles can be created 
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by utilizing a gene targeting strategy that introduces a neomycin resistance cassette 
carrying a cryptic exon into an intron of the endogenous murine allele [251]. During the 
processing of RNA, some transcripts will contain the cryptic exon, while others will skip 
over this exon and create a normal protein. Those with the cryptic exon have premature 
termination sequences in all three reading frames, leading to premature truncation of the 
protein. We found that mice with only 5% of normal BubR1 levels are born alive but die on 
the day of birth, most likely due to the accumulation of vast amounts of aneuploid cells 
during embryogenesis [218]. On the other hand, mice that express about 10% of normal 
BubR1 protein are viable and develop into adult mice. 10% BubR1 MEFs have low spindle 
assembly checkpoint activity, and coincidently are highly aneuploid [218]. These MEFs 
have high rates of PMSCS and lagging chromosomes [218]. Mice with 10% BubR1 have 
no detectable aneuploidy at birth, but accumulate more and more cells with abnormal 
chromosome numbers as they age [218]. For instance, 3% and 33% of their splenocytes are 
aneuploid at 2 and 12 months, respectively. In contrast, splenocytes from heterozygous 
BubR1 knockout mice, which express 30% of normal BubR1 protein, have no detectable 
aneuploidy or PMSCS [218]. BubR1+/- MEFs develop mild but significant aneuploidy, but 
no significant PMSCS. Only about 3% of mice with 10% of normal BubR1 develop 
spontaneous tumors [218], but, when treated with DMBA, they develop lung tumors at a 
significantly higher incidence then their wild-type littermates [213]. We also found that 
these animals exhibit many features of premature aging, which will be highlighted shortly. 
 
2.4.6  Bub1 
Bub1 is a protein kinase that localizes to unattached kinetochores early in prophase, where 
it plays a role in assisting the mitotic checkpoint apparatus both in response to spindle 
damage and for mitotic timing [252]. Bub1 is required for recruitment of Mad1-Mad2 
protein complexes to unattached kinetochores. These complexes alter the conformation of 
“free” Mad2, thereby allowing it to interact efficiently and stably with Cdc20. The 
resulting Mad2-Cdc20 complexes, which may further contain BubR1 and Bub3, then bind 
and inhibit the APC/C. Bub1, along with BubR1, function in the checkpoint to sense proper 
microtubule tension [253]. Bub1 also functions to sense microtubule attachment to the 
kinetochore, thereby functioning at two levels in the checkpoint [197, 254]. Bub1 exists in 
a complex with Bub3 and Mad1 [255]. Bub1 is a kinase capable of self-phosphorylation 
that has been demonstrated to also phosphorylate Mad1 in vitro, but apparently this is 
either not important for in vivo checkpoint signaling or it does not occur [256]. The 
localization of Bub3, Mad1, Mad2, BubR1, Cenp-E, Cenp-F and Cenp-I to kinetochores 
requires Bub1, but not its kinase activity [198, 257, 258]. Phosphorylation of Bub1 at 
kinetochores, resulting in its activation, has been shown recently to aid in the generation of 
the spindle checkpoint signal, and is believed to be important during late pro-metaphase 
when only a few chromatids lack microtubule capture [259]. Bub1 phosphorylates Cdc20, 
thereby preventing the latter from activating the APC/C [260].  Expression of Cdc20 
incapable of phosphorylation by Bub1 or expression of a kinase-dead Bub1 results in 
premature mitotic exit and defective checkpoint function, indicating the importance of 
Bub1 kinase activity [261, 262]. Bub1 is cleaved during the process of apoptosis, but 
whether this is an essential event or if it is just a feature of programmed cell death is 
debatable [263]. 
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To study the role of Bub1 in chromosome segregation and tumorigenesis at the level of the 
whole organism, we generated a series of mutant mice in which expression of Bub1 is 
reduced in graded fashion by the use of wild-type, hypomorphic and knockout alleles 
[216].  We found that hypomorphic mice with low amounts Bub1 protein are viable, fertile 
and overtly normal despite low levels of Bub1, severely weakened spindle assembly 
checkpoint activity, and massive aneuploidy. Bub1 haploinsufficient mice, which express 
more residual Bub1 protein than Bub1 hypomorphic mice, also exhibit reduced checkpoint 
activity and increased aneuploidy, but to a lesser extent. Although cells from Bub1 
hypomorphic and haploinsufficient mice have remarkably similar rates chromosome 
missegregation, cell survival after an aberrant separation is shown to increase dramatically 
with decreasing Bub1 levels. Bub1 hypomorphic mice are prone to a variety of 
spontaneous tumors, including lymphomas, lung adenocarcinomas, hepatocellular 
carcinomas and sarcomas. In contrast, Bub1 haploinsufficient mice are somewhat protected 
against spontaneous tumorigenesis. These findings demonstrate Bub1 drives neoplastic cell 
transformation when its level of expression drops below a critical threshold, and suggest 
that besides ensuring proper chromosome segregation, Bub1 is important for mediating cell 
death when chromosomes happen to be missegregated (Chapter 8). 
 
2.4.7  Cenp-E 
Centromere-associated Protein-E (Cenp-E) is an essential, highly conserved, 312 kDa, 
mitosis specific, cell-cycle regulated kinesin-like motor protein that accumulates in late G2 
and mitosis [223, 264-266]. The end of mitosis triggers the rapid destruction of Cenp-E. 
Both the proteins responsible for this degradation and the mechanism behind its 
synchronous downregulation is currently unknown [267]. Two main functions are 
performed by Cenp-E during mitosis. Firstly, Cenp-E participates in making and/or 
maintaining the interaction between the microtubules of the mitotic spindle and mitotic 
chromosomes [223, 268]. Secondly, during spindle assembly checkpoint activation, Cenp-
E activates the kinase activity of BubR1 [201, 269] and subsequently silences the 
production of the “stop anaphase” signal that is generated by BubR1 in response to proper 
attachment to the mitotic spindle [270]. In contrast to other spindle assembly checkpoint 
proteins, Cenp-E expression and function seems to be narrowly restricted to mitosis. 
Therefore, downregulations or mutations of this gene may only affect the process of 
accurate chromosomal separation, and may have no additional consequences. 
 
Cenp-E Mouse Studies. Cells in which Cenp-E is completely depleted by Cre-mediated 
recombination are characterized by unstable kinetochore-microtubule attachments and high 
rates of chromosome missegregation [223]. Furthermore, such cells are unable to induce a 
sustained prometaphase arrest in the presence of spindle damage, indicating that Cenp-E is 
an essential component of the spindle assembly checkpoint. Cenp-E+/– MEFs, which 
express 50% of normal protein, rapidly develop aneuploidy [224]. This aneuploidy is also 
detectable in lymphocytes, splenocytes and colonic epithelial cells from Cenp-E+/– mice 
[224], demonstrating that disruption of a single allele of Cenp-E results in missegregation 
of chromosomes during mitosis. These mice also exhibit a predisposition to spontaneous 
tumor formation in both the spleen and lung, suggesting a link between aneuploidy and 
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tumor formation. This is not a generalizable conclusion, however, as the number of 
spontaneous liver tumors decreases in Cenp-E heterozygous mice. In addition, in contrast 
to all models of defective checkpoint function that have been tested, challenging Cenp-E+/– 
mice with DMBA also resulted in lower numbers of tumors than in wild-type control mice 
[224]. In fact, these mice appear to be protected against both carcinogen induced and 
p19Arf–/– initiated tumor formation. Together, these data suggest that aneuploidy as the 
result of reduced Cenp-E expression can act both as a promoter and inhibitor of the 
tumorigenic process in mice. 
 
2.4.8  Summary 
In conclusion, with the exception of certain tissues of Cenp-E+/– mice, Mad1+/– mice, Mad2 
heterozygous and transgenic mice, and Bub1 hypomorphic mice, a commonality between 
the distinct mouse models for mitotic checkpoint failure is the lack of an increase in 
spontaneous tumors. However, with the exception of Cenp-E+/– mice, mouse models with 
defective spindle assembly checkpoints are prone to carcinogen-induced tumors. Thus, it 
seems that the kinds of gene mutations introduced by carcinogens do not occur over the 
normal lifetime of a laboratory mouse. Progress in understanding how mitotic checkpoint 
failure predisposes cells to transformation appears to depend on the identification of 
cancer-critical genes targeted by carcinogens such as DMBA and AOM. Mitotic 
checkpoint failure does not seem to accelerate tumorigenesis in mice heterozygous for 
tumor suppressor genes such as p53, Rb1 and Apc. This is quite surprising, as one would 
expect increased chromosome missegregation to increase the frequency with which the 
remaining wild-type gene copy is lost. One possibility is that the loss of whole 
chromosomes on which these tumor suppressor genes are located might trigger a cellular 
response that leads to apoptosis or senescence. Because aneuploidy can exert tumor-
suppressive, tumor-promoting, or benign effects depending upon the tissue or cell type and 
the additional cancer-critical gene mutations that are present in a cell, it is imperative to 
identify the genetic alterations that synergize with spindle assembly checkpoint mutations 
in cancer development. Findings revealed from such studies in mice may lead to novel 
therapeutics that may be able to target human cancers in ways that previously would have 
been overlooked. 
 
2.5  HUMAN CANCER AND THE MITOTIC CHECKPOINT 
 
2.5.1  Introduction 
Because the spindle assembly checkpoint prevents the development of aneuploidy and 
because the vast majority of human tumors are aneuploid, many efforts have looked for 
mutations in spindle assembly checkpoint genes in human cancers. Most established tumor 
cell lines exhibit spindle assembly checkpoint defects [271, 272], but the molecular reason 
for these aberrancies has been difficult to determine. Using many methods, including direct 
sequencing and gene expression profiling, have been used to identify the protein that may 
be responsible. Several studies have reported alterations in various mitotic checkpoint 
protein genes, including Mad2, Bub1, and BubR1, in human cancers (Table 3 and 4) [175, 
273-275], which suggests a potential link between deregulated mitotic checkpoint 
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inhibition of APC/C and chromosomal instability and cancer. The results of these 
investigations, both positive and negative, are summarized below. 
 
2.5.2  Mad2 
Sequence mutations of Mad2 are rare in human cancer. Established hepatocellular 
carcinoma (n=8 [271]) and lung cancer cell lines (n=21 [276], n=30 [277]) have no 
mutations in Mad2. In primary tumors, Mad2 is not mutated in aneuploid colorectal 
cancers (n=19 [278]), digestive tract tumors (n=32 [279]), soft-tissue sarcomas (n=42 
[280]), hepatocellular carcinomas (n=10 [280], n=50 [271]), lung cancers (n=25 [276], 
n=30 [277]), or breast tumors (n=48 [277]). A small deletion was found in 1 of 22 breast 
cancer cell lines [281], but additional studies have revealed no additional mutations (n=12 
[282]). A point mutation in codon 190 of Mad2 was found in 1 of 44 primary bladder 
cancers [280], although transfection of this mutant cDNA into cells did not affect mitotic 
arrest. Conversely, Mad2 is frequently mutated in primary gastric cancers (n=22 of 49 
[283]) and cell lines (n=1 of 5 [283]).  
 
Although mutations in Mad2 are rare, differential expression patterns of Mad2 have been 
found in several tumor types. Hyper-methylation of the Mad2 promoter is correlated with a 
downregulation in Mad2 and has been seen in hepatocellular carcinomas (n=5 of 10 [284]). 
Other cancer cell lines that have lower than normal Mad2 expression include ovarian 
cancer (n=3 of 7 [285]), hepatoma cell lines (n=6 of 11 [286]), adult T-cell leukemia 
(ATLL, n=2 of 6 [287]), and nasopharyngeal cancer (n=2 of 5 [288]).  Patients with 
Barrett’s esophagus, a precancerous condition, may exhibit a downregulation (n=8 of 33) 
or an upregulation (n=8 of 33) in Mad2 [289]. Esophageal cancers are similar, where lower 
levels (n=2 of 4) and higher levels (n=1 of 4) of Mad2 have been found [289]. Mad2 is 
elevated in a high percentage of gastric tumors (n=25 of 34 [290]), but this upregulation 
does not correlate with any clinicopathological characteristics. Mad2 is also overexpressed 
in both breast tumor cell lines (n=5 of 12) and primary tumors (n=5 of 9 [282]), as well as  
primary retinoblastomas [235], colorectal cancers [291, 292], and bladder cancers [235]. 
Because Mad2 is a direct target of E2F mediated transcription [235], any event that 
deregulates Rb function (Fig. 3) can lead to aberrant expression of Mad2. Therefore, it is 
not surprising to find frequent overexpression of Mad2 in human cancers as Rb is often 
mutated or deleted. 
 
2.5.3  Bub3 
Mutations of Bub3 appear to be extremely rare in human cancers. Colorectal cancers do not 
have reported mutations in the Bub3 coding sequence (n=19, [278]); nor do glioblastomas 
(n=22 [293]), lung tumors (n=44 [294]) or osteosarcomas (n=32 [295]). Hepatocellular 
carcinoma (n=8 [271]), bladder cancer [280], breast cancer (n=12 [282]) and osteosarcoma 
cell lines (n=7 [295]) also have no mutations in Bub3.  
 
Aberrant levels of Bub3 also appear to be rare in human cancers. Lung adenocarcinomas 
have reduced expression (n=7 of 18 [296]) of Bub3. In the same sample set, Bub3 was 
overexpressed in certain tumors (n=5 of 18 [296]). Other tumors that also display higher 
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than normal levels of Bub3 include gastric carcinomas (n=34 of 43 [297]), primary breast 
tumors (n=7 of 9 [282]), and breast cancer cell lines (n=3 of 12 [282]). 
 
2.5.4  BubR1 
Coding sequence mutations in BubR1 are rare in human cancers or established cancer cell 
lines. BubR1 is not mutated in the following cell lines: breast tumor (n=12 [282], n=19 
[298]), hepatocellular carcinoma (n=8 [271]), lung cancer (n=47 [299]), thyroid tumor (n=8 
[300]), pancreatic cancer (n=9 [301]), or other various cell lines (n=6 [302]). Missense 
mutations in BubR1 exist in colorectal carcinoma cell lines (n=2 of 19 [272]). Most 
primary cancers also have no mutations in BubR1. This includes colorectal tumors (n=19 
[278], n=22 [302]), hepatocellular carcinoma (n=7 [302]), lung cancers (n=44 [294]), B-
cell lymphomas (n=8 [303]), clear cell renal carcinomas (n=2 [302]), or glioblastomas 
(n=22 [293]). Primary ATLL have frequent mutations in BubR1 (n=2 missense mutations 
and one 47bp deletion in 10 ATLL [303]). 
 
Variations in BubR1 expression have been found in several tumor types. Thyroid cancer 
cell lines have an impaired ability to phosphorylate BubR1, but also have reduced overall 
protein levels (n=3 of 8 [300]). A greater than 50% reduction in BubR1 was found in 
colorectal carcinomas (n=10 of 116 [302]). Alternatively, BubR1 is overexpressed in 
gastric carcinomas (n=29 of 43 [297]), primary breast tumors (n=8 of 9 [282]), breast 
cancer cell lines (n=8 of 12 [282]), and lung cancer cell lines (n=8 of 8 [304]).  
 
A rare human disorder, called mosaic-variegated aneuploidy (MVA) has recently been 
shown to have truncating and missense mutations in the coding sequence of BubR1 in 5 of 
8 patients (Fig. 9) [305]. In a second study, all 7 Japanese MVA patients had monoallelic 
BubR1 mutations with polymorphisms in the second allele that correlate with reduced 
BubR1 expression [306]. MVA was first described in a pigtail macaque monkey that had 
severe delays in development and apparent mental retardation, as well as abnormal 
karyotypes of lymphocytes and fibroblasts, that were consistently trisomic, but for varying 
chromosomes [307]. MVA in humans is characterized by karyotypical abnormalities 
including aneuploidy and PMSCS, short life-span, severe microcephaly, mental retardation, 
optical atrophy and cataracts, facial dysmorphisms and heart defects, although the degree 
of these phenotypes is highly variable [308-314]. Notably, several of these patients 
developed tumors early in life, most commonly Wilm’s tumors, but also 
rhabdomyosarcomas, nephroblastomas and myelodysplasias [310-312, 315-318]. Out of 22 
patients, 11 have had tumors, but many of these individuals died early in life or had no 
follow-up following early diagnosis [319], suggesting that these figures may under-
represent the cancer formation in MVA patients. This is the first disorder that is attributed 
to germline mutations of a spindle checkpoint protein that also predisposes individuals to 
tumor development [305]. However, not all cases of MVA correlate with mutant BubR1 
alleles, opening the possibility that an alternative mutation or the aberrant expression in 
other members of the spindle assembly checkpoint machinery may be present. 
Interestingly, non-MVA related Wilm’s tumors (n=30), acute lymphoblastic leukemias 
(n=10), primary rhabdomyosarcomas (n=9) and rhabdomyosarcomas cell lines (n=11) do 
not have any mutations in BubR1 [320], demonstrating that these tumors arise 
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preferentially when BubR1 is mutated, although this step is not essential for the formation 
of these tumors. It is not known if these tumors that lack mutations in BubR1 express 
BubR1 at lower than normal levels, which may explain why these tumors develop 
spontaneously in non-MVA related individuals. Another important point to remember is 
that every cell of an MVA patient has impaired BubR1 function, yet most individuals 
develop only one or two tumors. Therefore, at the cellular level, the cancer risk remains 
low and other events are clearly required for oncogenesis to occur. 
 
2.5.5  Bub1 
The spindle assembly checkpoint gene with the most frequent mutations in human tumors 
occurs in the coding sequence of Bub1. In colorectal cancer cell lines, a dominant negative 
heterozygous deletion was identified (n=1 of 19 [272]), but mice that carry this mutation 
are not susceptible to spontaneous tumorigenesis [321]). Additionally, missense mutations 
of Bub1 are seen in colorectal carcinoma (n=1 of 19 [272]), lung cancer (n=1 of 88 [299]), 
and pancreatic cancer cell lines (n=1 of 9 [301]). In primary tumors, missense mutations 
occur in lung adenocarcinomas (n=1 of 30 [322]), colorectal carcinomas (n=1 of 32 [279], 
n=1 of 22 [302]), and ATLL (n=1 of 10 [303]). Additionally, small deletions have been 
found in primary thyroid tumors (n=1 of 19 [300]) and leukemia cell lines (n=2 of 7 [323]). 
These dominant-negative deleted alleles in these leukemia cell lines occur in the 
kinetochore localization domain of Bub1, thereby inhibiting the proper localization of 
Bub1 to the kinetochore [323]. 
 
Additional studies have not identified any other mutations. Established cell lines from 
bladder cancer (n=9, [280]), colorectal cancer (n=19 [278], n=8 [324]) hepatocellular 
carcinoma (n=8 [271]), gastric cancer (n=5 [283]), oral cancer (n=9 [325]), head and neck 
squamous cell carcinoma (n=6 [326]), lung cancer (n=25 [326], n=30 [322]), breast tumor 
(n=19 [298], n=12 [282], n=9 [323]), hematopoietic (n=5 [327]), thyroid (n=8 [300]), or 
various other carcinoma cell lines (n=59 [328], n=6 [302]) have no mutations in Bub1.  
Primary bladder cancers (n=43, [280]), colorectal cancers (n=32 [324]), hepatocellular 
carcinomas (n=50 [271], n=7 [302]), gastric cancer (n=49 [283], n=12 [329], n=8 [325]), 
lung cancers (n=44 [294], n=20 [324]), breast carcinomas (n=20 [330]), glioblastomas 
(n=40 [293]), clear cell renal carcinomas (n=2 [302]), B-cell lymphomas (n=8 [303]), and 
acute myeloid leukemia (n=92 [327]) also exhibit no mutations in the sequence in Bub1. 
 
 
 
Fig. 9.     Overview of BubR1 mutations underlying MVA syndrome. See text for details. Note that BubR1 
mutations found in the same patient have the same font color.  
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Table 3- Mutational changes in spindle assembly checkpoint genes in human cancer. 
Several types of tumors display aberrant Bub1 expression. In patients with Barrett’s 
esophagus, Bub1 is overexpressed (n=12 of 33) in a subset of patients, while it is repressed 
in another (n=9 of 33 [289]). A similar profile is also seen in esophageal cancer (n=1 of 4 
upregulated, 1 of 4 downregulated [289]). This pattern is also seen in gastric cancers, 
where a small group exhibits a downregulation of Bub1 (n=4 of 20 [331]) and another 
displays increased amounts of Bub1 (n=36 of 43 [297], n=8 of 20 [331]). In colorectal 
carcinomas, Bub1 is silenced below 50% of normal levels in a group of patients (n=10 of 
103 [302]). Breast tumors (n=7 of 9) and breast tumor cell lines (n=10 of 12) have Bub1 
overexpressed in a majority of cases [282]. In malignant melanoma, Bub1 is highly 
expressed as well (n=21 of 30 [332]). Bub1 also is expressed highly in leukemia [333] and 
malignant salivary gland tumors [334]). 
 
2.5.6  Cdc20 and Cdh1 
APC/C coactivators have also been observed to be deregulated in human cancers. For 
instance, the overexpression of Cdc20 is observed in a variety of human malignancies, 
including pancreatic (n=12 of 20 [335]), lung adenocarcinomas [336], gastric cancer (n=22 
of 25 [337]), breast tumors (n=5 of 9 [282]) and breast tumor cell lines (n=10 of 12 [282]). 
There are no mutations in Cdc20 in colorectal cancer (n=19 [278]), hepatocellular 
carcinoma (n=8 [271]), lung tumors (n=25 [276]), or lung (n=21 [276]) and breast cancer 
cell lines (n=12 [282]). Cdh1 downregulation is observed in murine lymphomas, whereas 
overexpression of Cdh1 acts to suppress B-cell tumorigenesis [338]. In this regard, Cdc20 
appears to be a potential oncogene, whereas Cdh1 may more likely be a tumor suppressor.  
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Table 4- Epigenetic changes in spindle assembly checkpoint genes in human cancer. 
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2.5.7  Summary 
Inactivating mutations in spindle checkpoint genes have been rare to detect in human 
cancers, which, in retrospect, is not surprising given that homozygous null mutations in 
murine mitotic checkpoint genes are invariably incompatible with cell viability. Reduced 
expression of mitotic checkpoint genes, however, is compatible with viability and results, 
in most cases, in mitotic checkpoint failure, increased chromosome missegregation and 
increased susceptibility to carcinogens in mice. Mitotic checkpoint genes are expressed at 
reduced levels in several human cancers, most likely through epigenetic mechanisms. 
Based on insights from mouse models, it is reasonable to argue that such downregulations 
could promote malignant cell transformation in humans. Especially, when taken into 
consideration that humans have a much longer lifespan and a much greater exposure to 
environmental carcinogens than laboratory mice. Recent evidence of the human mosaic 
variegated aneuploidy (MVA) syndrome characterized by cancer predisposition caused by 
germ-line mutations of BubR1 further strengthens the idea that mitotic checkpoint 
dysfunction promotes carcinogenesis in humans. Several human tumors do have increased 
levels of spindle checkpoint genes as well, demonstrating that the controlled expression of 
these proteins needs to be tightly regulated to also prevent chromosomal abnormalities 
from occurring. The recent evidence of Mad2 overexpression in mice playing a causal role 
in the establishment of tumorigenesis further strengthens this idea. Whether the 
overexpression of other mitotic checkpoint genes have similar consequences in animal 
model systems remains to be determined, making it difficult to generalize that upregulation 
of spindle assembly checkpoint genes plays a role in the causation or the promotion of 
cancer formation in humans. It also appears that the genetic context of how aneuploidy 
develops needs to be taken into account. Bub1 hypomorphic, Mad2 transgenic and Cenp-E 
mice develop spontaneous tumors, but the locations of these tumors differ. Additionally, 
within Cenp-E heterozygous mice, there appears to be a protection against certain 
tumorigenic processes. This demonstrates, that like other types of genetic instability, cancer 
is a potential, but not obligatory outcome of a situation where there is whole chromosome 
aneuploidy. Growth-promoting aneuploid cells that could initiate cancer may be offset by 
cells that acquire a chromosomal content that is incompatible with proliferation or survival. 
What will be important is to define how different paths that lead to aneuploidy, different 
genetic contexts, and different cell types when taken together effect whether aneuploidy 
promotes growth or stimulates apoptosis.  
 
 
2.6  AGING AND THE SPINDLE ASSEMBLY CHECKPOINT 
 
2.6.1  Introduction 
Two recent discoveries have identified the spindle assembly checkpoint BubR1 as a key 
regulator of aging. First, genetically modified mice that produce reduced amounts of 
BubR1 have a lifespan that is about 5-fold shorter than normal and develop various aging 
related disorders at a very young age [218, 339, 340]. Second, during the course of natural 
aging, BubR1 protein production declines dramatically in many tissues. Various molecular 
effectors that promote cellular senescence, such as p16Ink4a, p19Arf, p21 and p53, are 
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induced in cells from hypomorphic BubR1 mice. Cellular senescence is an important anti-
cancer mechanism, as it prevents cell cycle re-entry of potentially neoplastic cells. 
However, as a consequence of cellular senescence, cells acquire characteristics that 
promote disruption of normal tissue architecture, thereby promoting pathologies associated 
with aging and potential oncogenic transformation of pre-neoplastic cells [341, 342]. Along 
with BubR1 hypomorphic mice, a variety of mouse models have characteristics of 
premature aging. Here, the similarities and differences between these models will be 
highlighted. 
 
2.6.2  Aging and pathways of cellular senescence 
In contrast to immortal tumor cells, normal cellular proliferation in culture declines after a 
number of divisions and eventually stops completely when cells enter in to a state known 
as replicative senescence. The acquisition of a senescent phenotype results in a series of 
changes in cell morphology and function. These cells spread out as a monolayer and 
acquire a large cytoplasmic volume. They remain metabolically active and secrete many 
factors that are not normally secreted, such as degradative enzymes (matrix 
metalloproteinases), growth factors, and inflammatory cytokines. The secretion of these 
factors can lead disruption of both normal tissue structure and function [343], which may 
result in age-related pathology by stimulating chronic inflammation and tissue remodeling. 
Additionally, senescent cells may promote cancer by stimulating cells with pre-neoplastic 
lesions in their vicinity [344]. Cells with characteristics of senescence accumulate in 
multiple tissues of both humans and rodents with age [344]. However, a conclusive 
demonstration that senescence causes aging has not been shown, as the current published 
data is entirely correlative. Senescence can be triggered by a variety of intrinsic and 
extrinsic stresses, including oxidative damage, telomere dysfunction, DNA damage, 
oncogene activation, and drugs that affect the structure of DNA or microtubules (Fig. 10) 
[344-346]. The two main cellular pathways that are responsible for the execution 
senescence are the p16Ink4A-Rb and the p19Arf-p21-p53 tumor suppressor pathways [344, 
347, 348]. Senescence pathways seem to be employed in a cell- and species-specific 
manner. In both human and mouse cells, direct DNA damage mainly activates p53 through 
the Atm and Atr kinases [344, 349]. In certain human cells, oxidative stress, attrition of 
telomeres and loss of telomere function may activate cellular senescence via the same 
program, but also potentially through p16Ink4a [344, 349]. In mouse cells however, the 
response to aberrancies in telomere function is dependent on p19Arf. Oncogene-induced 
stress leads to activation of both the p16Ink4a-Rb and p19-p53 pathway, although the relative 
importance of each pathway seems to vary between mouse and human cells. The 
expression of both p19Arf and p16Ink4A is increased in a variety of tissues with age in mice 
and rats [350], although it has been difficult to determine what effect these pathways have 
on normal aging, as disruption in the core components of each pathway results in early 
tumor formation. Recent studies indicate that p16Ink4A may be responsible for normal aging 
in certain tissue types, as knockout animals do not display the normal age-related depletion 
of stem cells in the brain, pancreas, and bone marrow [351-353]. 
 
  51 
 
 
Fig. 10- The p19-p53 and p16-Rb pathways in promotion of cellular senescence. Various intrinsic and 
extrinsic stresses can activate the cellular senescence program. These stresses engage various cellular 
signaling cascades, but ultimately activate p53, Rb or both. Activated p53 induces senescence via a complex 
gene expression program that includes the induction of p21, whereas Rb induces senescence via repression of 
E2F target genes and alterations in chromatin structure. Once the senescence program is activated, cells 
withdraw from the cell cycle and a series of changes in cell function and morphology occur. 
 
2.6.3  Spindle assembly checkpoint dysfunction and aging 
We generated a series of mice expressing low amounts of BubR1 in an attempt to 
determine if these animals were susceptible to tumorigenesis, as BubR1 is mutated or 
expressed at low levels in a variety of tumors. Unexpectedly, mice that express only 10% 
of normal BubR1 display an array of aging-associated phenotypes much earlier than age-
matched controls. These phenotypes include reduced lifespan, cachetic dwarfism, muscle 
atrophy, lordokyphosis, cataracts, craniofacial dysmorphisms, loss of subcutaneous fat, 
impaired wound healing, heart arrhtymias, arterial stiffening, gliosis and infertility [218, 
339, 340]. Additionally, cells from these mice undergo premature cellular senescence, 
coupled with a profound induction of p16Ink4a, p19Arf, p21Cip1, and p53. Furthermore, these 
cells have substantial amounts of lagging chromosomes, aneuploidy, and PMSCS. As 
mentioned previously, MVA patients display several phenotypes characteristic of old age, 
including reduced lifespan, cataracts, small stature, and facial dysmorphisms [310, 318], 
which strengthens the idea that downregulation of BubR1 function is sufficient to drive 
some cellular processes that result in age-related characteristics. These findings combined 
with the observation that BubR1 protein levels decline dramatically as normal mice age has 
suggested the BubR1 functions as a key regulator of the natural aging process. The strong 
correlation between the onset and progression of the aging-associated phenotypes and the 
degree and the severity of the chromosome number instability in hypomorphic BubR1 mice 
suggested a role for aneuploidy in the development of progeroid features. Perhaps, 
aneuploidy might elicit signals that drive cells into a senescent state and cause early aging-
related phenotypes as they accumulate. From this study, it was unclear if this pathology of 
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aging is unique for hypomorphic BubR1 animals, or if it is a general consequence of 
impaired spindle checkpoint function. We considered three main possibilities to explain the 
events that promote the aged phenotype in these animals. One possibility is that a low level 
of BubR1 protein accelerates the aging process and BubR1 is unique in this function. 
Alternatively, aging could be a general consequence of defective spindle checkpoint 
function. Finally, aneuploidy may contribute to these features, as animals demonstrate 
detectable aneuploidy early and concurrently with the development of aging.  
 
In order rigorously test these possibilities; we used Bub3 and Rae1 haploinsufficient mice 
(Chapter 6). At 5 months, BubR1 hypomorphic mice have an aged appearance with 
aneuploidy in 15% of their splenocytes [218]. Aged matched single heterozygous Bub3 and 
Rae1 mice each have 9% aneuploidy, but no features of aging. One could argue that this 
may be the result of having aneuploidy that remains below a critical level. However, 
splenocytes from 5-month-old compound Bub3/Rae1 mice have 36% aneuploidy and a 
wide spectrum of chromosome losses and gains [196], but show no overt features of aging 
at this age [213], which further conflicts with the notion that aneuploidy alone is a driving 
force of aging. We also found that although Bub3+/–/Rae1+/– MEFs are more aneuploid than 
BubR1 hypomorphic MEFs, they exhibit lower levels of cellular senescence, along with an 
intermediate induction of p53, p21, p19Arf and p16Ink4A. On the other hand, Bub3 and Rae1 
single haploinsufficient cells do not display senescence or an induction of these cell cycle 
arrest-related markers. During the second year of life, which is long after all BubR1 
hypomorphic animals have died, progeroid features develop only in double heterozygous 
Bub3/Rae1 animals, but not in mice with single heterozygous deletions of Bub3 or Rae1. 
Together, these findings suggest that early onset of age-related phenotypes in mice with 
spindle assembly checkpoint defects is linked to cellular senescence and the activation of 
the p16Ink4A and p53 tumor suppressor pathways, rather than to aneuploidy. 
 
As we found common senescence pathway activations in spindle checkpoint defective mice 
that display hallmarks of early aging, we then asked if disruption of members of the 
p16Ink4A-Rb or p19Arf-p53 pathway were able to modulate any phenotypes. We used our 
BubR1 hypomorphic animals, as these mice age much faster than p16Ink4A, p19Arf, or p53 
null animals die from tumors. As an alternative to possible effects on aging, using this 
approach allowed us to also evaluate whether aneuploidy resulting from BubR1 
insufficiency would synergize with known tumor susceptible models to promote 
tumorigenesis. Along with an early induction of p16Ink4A in BubR1 hypomorphic cells, we 
found that a variety tissues from hypomorphic mice also has an elevation of this gene via a 
quantitative real-time PCR (qRT-PCR) based approach. These tissues include skeletal 
muscle, subdermal adipose tissue, fat deposits, eye, and kidney. Other tissues, including 
dermis, heart, testis, ovary, aorta, pancreas, colon and liver, do not have an increased 
expression, demonstrating that although certain tissues do have an increased amount of 
p16Ink4A as a result of BubR1 insufficiency, it is not necessarily true that all tissues respond 
similarly to low amount of BubR1. Interestingly, we found that by knocking out p16Ink4A in 
these mice, the tissues that had elevated levels of p16Ink4A displayed a delay or attenuation 
of the aging phenotype of these tissues. Subdermal adipose thickness was maintained in 
compound mutant mice, whereas BubR1 hypomorphic mice have a decline in adipose with 
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age. Consistent with an overall improvement in adipose maintenance, BubR1H/H/p16–/– 
mice also had more deposits of visceral and subcutaneous fat than hypomorphic animals. 
We also found that while BubR1 hypomorphic adipose tissue deposits have a strong 
staining for β-galactosidase, a feature of senescent cells, BubR1H/H/p16–/– mice had marked 
reduction in β-galactosidase positive cells. It is important to note that although there is not 
a complete reversal of this aging-associated phenotype, as these animals still had 
significantly less adipose than wild-type littermates. The development of cataract in 
compound mutant mice was delayed to small degree, but this phenotype still affected all 
animals of our cohort. The strongest effect of p16Ink4A disruption was seen in skeletal 
muscle tissue. Very early in hypomorphic skeletal muscle, p16Ink4A is strongly induced, 
long before aging appears in this tissue. As hypomorphic mice age, they develop kyphosis 
which is attributable to muscle atrophy (sarcopenia). This atrophy is severely delayed by 
disrupting p16Ink4A, as the median time to onset of this disease changes from 15 to 45 
weeks, a 3-fold delay. Additionally, not all mice of our compound mutant cohort develop 
this phenotype, which is in contrast to hypomorphic mice. Several markers of senescence 
in vivo that were upregulated in BubR1 hypomorphic mice are also attenuated by the 
further disruption of p16Ink4A. Together, these data suggest that tissues that have an 
induction of p16Ink4A that display characteristics of aging are able to be modulated by 
abolishing the activation of this gene. Along with an overall improvement in certain age-
related disorders, BubR1H/H/p16–/– mice also had a 25% extension of median lifespan, 
going from 20 to 25 weeks. Characteristics of aging in other tissues, which do not have an 
induction of p16Ink4A, that either have aging related diseases or are unaffected in 
hypomorphic BubR1 animals, remain unchanged with the disruption of p16Ink4A. However, 
disrupting this tumor suppressor appears to synergize with low levels of BubR1 in the lung 
to promote lung tumorigenesis specifically. The incidence of lung tumors, which are not 
seen in p16Ink4A null animals, increases from <1% in BubR1H/H mice to over 9% in 
BubR1H/H/p16–/– mice. In conclusion, disruption of the p16Ink4A gene in hypomorphic mice 
delays certain age-related characteristics while promoting lung carcinogenesis when 
BubR1 levels decline. 
 
We then asked whether disruption of p19Arf-, also encoded by the same locus as p16Ink4A, 
whose protein levels increases with age in normal animals, was able to modulate any age-
related pathologies in our BubR1 hypomorphic animals. Interestingly, most phenotypes of 
aging, including lordokyphosis, cataract formation, adipose tissue deposition and 
subdermal adipose tissue thickness were further abrogated by disrupting p19Arf. 
Additionally, ablation of p19Arf resulted in a significantly increased rate of in vivo 
senescence in our BubR1H/H mice. This is in stark contrast to the tumorigenesis information 
obtained from the p16Ink4A study. Taken together, these studies suggest that activation of 
the p16Ink4A acts to promote aging when BubR1 levels decline, versus engagement of the 
p19Arf acts to delay age-related pathologies in BubR1 hypomorphic mice. In an attempt to 
understand why there may be such a discrepancy in the outcome of engagement of these 
pathways, we sought to identify common features of mice that display phenotypes 
characteristically associated with early aging. 
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2.6.4  Additional mouse models of aging 
Several mouse models that have single gene mutations that do not affect spindle assembly 
checkpoint function exhibit certain characteristics of premature aging (Table 5). The tumor 
suppressor p53 responds to a variety of cellular stresses, including DNA damage, to induce 
apoptosis or senescence depending upon the severity of the damage (Fig. 4) [354]. Mice 
with a deletion mutation of the first six exons of p53 (p53m/+) express a truncated RNA 
capable of making the carboxy-terminal p53 protein fragment. This mutation results in 
constitutively activated p53 [355]. This constant supply of active p53 appears to protect 
p53m/+ animals from spontaneous tumor formation, where nearly 50% of wild-type 
littermates from this cohort develop tumors versus only 6% of p53m/+ mice. However, as 
these mutant animals age, they display several features of premature aging, including 
reduced stress tolerance, lordokyphosis, osteoporosis, and reduced lifespan, although they 
are protected from spontaneous tumor formation [355]. Transgenic mice that express a 
mutant form of p53 that has a alanine to valine change at codon 135 (pL53), a temperature 
sensitive mutant that makes mutant p53 at normal body temperatures, also display most of 
these features [355], demonstrating that chronic activation or loss of p53 inhibition 
promotes the development of aging in certain tissue types. It is however important to note 
that p53 knock-in mice, which include all promoter regulation sequences, display no overt 
phenotypes [356]. In fact, these so-called “Super p53” mice are protected from spontaneous 
tumor formation and live substantially longer than wild-type mice [356]. Additionally, 
compound “Super p53” and “Super p19Arf” knockin mice have a longer lifespan and have a 
reduced accumulation of cells with aging-associated damage [357]. Transgenic mice 
expressing the short isoform of p53 (p44), which begins at exon 4 of p53, display 
premature cellular senescence which results from an upregulation of p21 and an early 
decline in testis function and bone mass [358], suggesting that chronic activation of the 
p19Arf-p53 senescence pathway promotes age-related phenotypes in these mice.  
 
Werner’s syndrome (WS) is a human disorder characterized by genetic instability and 
premature age-related pathologies. These include short stature, wrinkled skin, baldness, 
cataracts, muscular atrophy and a tendency to diabetes mellitus. The gene mutated in WS 
patients is WRN, a DNA helicase which participates in maintaining the integrity of the 
genome by suppressing illegitimate recombination or by repair of local DNA structural 
damage [359, 360]. Mice lacking Wrn however do not display early aging or premature 
senescence [359], illustrating that although WRN mutations in humans have severe 
ramifications, the genetic ablation of this gene alone in mice is insufficient to establish 
these phenotypes. 
 
Ataxia telangiectasia (AT) is a human syndrome, which makes some people have a 
characteristically aged appearance. The gene responsible for this diseases, ‘ataxia 
telangiectasia mutated’ (ATM), plays a pivotal role in the activation of cellular responses to 
DNA damage [361]. ATM senses double strand breaks (DSBs), which is one of the most 
potentially damaging assaults on DNA.  Patients with AT are characterized by neuronal 
degeneration, immunodeficiency, sterility, genomic instability, and cancer predisposition 
and have mutations in ATM [362]. Disruption of this gene in mice results in impaired 
proliferative capacity of hematopoietic stem cells (HSC) due to activation of p16Ink4a and 
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increased senescence [361]. Disruption of Rad50 or BRCA1, two other key members of the 
DSB repair machinery, also results in premature age-related phenotypes, along with an 
increased rate of spontaneous tumor formation and accelerated senescence [363, 364].  
 
Non-homologous end joining (NHEJ) is an error-prone mechanism of repairing DSBs 
because some DNA is lost when broken strands of DNA are simply pasted back together 
without the necessity of proofreading. Proteins important for this process include Ku86, 
Ku70, DNA-PKcs, XRCC4, XLF, and DNA ligase IV [365].  Mice deficient in Ku86 
exhibit early death, osteopenia, and skin atrophy, along with an accelerated rate of 
senescence [365]. However, these animals are not prone to tumor development, perhaps 
because the cohort died too early from other causes. DNA-PKcs deficient animals also 
exhibit early death, but have an increased rate of lymphoma development [366]. 
Interestingly, these mice have kyphosis and reduced body size, but no increased rates of 
cellular senescence, demonstrating that not all impairments of the NHEJ machinery behave 
similarly.  
 
The process of nucleotide excision repair (NER) removes damaged bases in DNA 
stemming from extrinsic factors, such as UV light. Several molecules play a role in this 
repair pathway and the importance of this repair mechanism is evidenced by the severe 
human diseases that result from in-born genetic mutations of NER proteins including 
Xeroderma pigmentosum (XP). Based on the underlying genetic defect, the disease can be 
divided into the seven complementation groups XPA through XPG [367]. Mice with 
mutations in XPD that mimic human trichothiodystrophy (XpdTTD), a brittle hair disorder, 
exhibit many symptoms of premature aging, including kyphosis, osteosclerosis, early hair 
graying, cachexia, infertility, and reduced life-span along with a predisposition to tumor 
formation [368-370]. These mice, when combined with XPA deficient mice, have an even 
more severe DNA repair defect, as they are more sensitive to oxidative DNA damage 
[368]. These mice have a greatly accelerated aging phenotype, further strengthening the 
argument that aging in mice can result from severe damage to DNA that goes unrepaired. 
Cockayne syndrome (CS), which is very similar to XP, results from mutations in one of 
two CS genes: CSA or CSB [371]. Compound XPA/CSB null mutant mice, which do not 
have an accelerated rate of tumor formation, display severe cerebellar abnormalities 
including apoptosis [372]. Mice deficient in Ercc1, a NER cross complementing gene, die 
before weaning with substantial aneuploidy and p53 activation in a variety of tissues [373] 
along with an induction of cellular senescence [374], illustrating that engagement of the 
p53 pathway is involved in the establishment of a permanent growth arrest. 
 
Along with impaired DNA repair capacity being linked to aging, other defects in overall 
maintenance of genetic stability also are tied to the early onset of age-related pathologies. 
Telomeres, which are found on the ends of chromosomes, are necessary to maintain 
chromosomal integrity and ultimately determine the replicative potential of a cell [375]. 
Mammalian telomeres are composed of long TTAGGG tandem repeats that become shorter 
after each cycle of cell division if they are not replaced. If enough of these TTAGGG 
repeats are lost, the telomere reaches a critically short length and becomes dysfunctional. 
Critically short telomeres are detected as DSBs and trigger unscheduled repair by NHEJ, 
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resulting in end-to-end fusions [376, 377]. This erosion of telomeres can be prevented 
when cells express sufficiently high levels of telomerase. This enzyme is composed of a 
telomerase RNA component (Terc) and a catalytic telomerase reverse transcriptase (Tert) 
subunit with the unique capacity to add TTAGGG repeats onto chromosome ends [378]. 
Ablation of Terc activity in mice leads to a high frequency of end-to-end chromosomal 
fusions and, at the organismal level, results in loss of fertility, proliferative defects, and 
symptoms of premature aging affecting the skin, germ line, intestine, immune system and 
bone marrow, although these mice are protected from carcinogen-induced tumor formation 
[379, 380].  The disruption of Atm in Terc null mice was also not sufficient to promote 
tumor formation [381]. However, there appears to be a tradeoff, as these animals display 
profound cellular senescence and a more severe induction of several phenotypes of early 
aging, including reduced stem cell precursors, tissue apoptosis, hair graying, hair loss, 
weight loss and early tumor-free death [381]. Mice lacking Terc along with Ku86 or DNA-
PKcs, two members of the NHEJ pathway, have earlier tumor-free death, along with 
accelerated aging in the germ line and intestine, without the induction of cellular 
senescence [380]. Alternatively, Parp-1, which recognizes and binds to DSBs, disruption 
combined with Terc insufficiency has no effect on aging or tumorigenesis [380]. In contrast 
to these models, disruption of Wrn along with Terc in mice results in cellular senescence, 
tumor formation, and a phenotype of premature aging that is very similar to WS patients 
[382]. This demonstrates that Wrn–/– mice do not normally show any of the phenotypes 
described for human WS patients because of the difference in length between mouse and 
human telomeres, as mouse telomeres are significantly longer than humans. By removing 
Terc, erosion of telomeres can occur in these animals and recapitulation of the human 
disease can be created. 
 
Other modifications of DNA appear to be required to also prevent the accumulation of aged 
phenotypes. Disruption of PASG, a protein responsible for DNA methylation, results in 
growth retardation, hair graying, hair loss, osteoporosis, kyphosis, and early death [383]. 
Cells from these animals also have an induction in p16Ink4a along with cellular senescence. 
These results are intriguing as it suggests that global hypomethylation of DNA, as the 
result of disruption of a protein that is involved with transcriptional silencing via promoter 
methylation is required to prevent these lesions. 
 
In addition to nuclear DNA damage, aberrancies in mitochondrial DNA may also 
contribute to the biology of aging, as mice that have a defective proofreading capacity in 
the mitochondrial-specific DNA polymerase, PolgA, exhibit several age-related phenotypes 
early in life [384]. These mice have a reduced lifespan, weight loss, hair loss, kyphosis, and 
osteoporosis. These mice are not prone to tumor formation, nor has the senescence 
phenotype been examined, making this an interesting model for further study. Also, 
whether other mutations affecting mitochondrial DNA remains an unexplored research 
venue. 
 
2.6.5  Summary 
The process of organismal aging is extremely complex. Several phenotypes occur in 
multiple mouse models, demonstrating that aging in these tissues can result from a variety 
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of factors. However, other phenotypes, such as cataracts in spindle assembly checkpoint 
defective animals, appear to be unique, suggesting that the “lesion” triggering certain 
aging-related phenotype differs [348, 385]. Also, a common feature of mouse models that 
exhibit early aging is the engagement of cellular senescence. The proteins responsible for 
this growth arrest are beginning to be elucidated and appear to include the members of the 
p53-p19Arf and the p16Ink4A-Rb pathway. Interestingly, it seems that DNA damage defective 
models engage primarily the p53 pathway, while spindle assembly checkpoint mutants 
engage both pathways. This difference may also explain why some phenotypes are seen 
commonly in mouse models of aging, while other features, such as cataract, appear to be 
specific for models with impaired spindle checkpoint function. It will be interesting to 
determine if disruption of these drivers of senescence results in a modulation of certain 
age-related pathologies in models that are genetically predisposed to age. Also, with the 
exception of p53 and p44 transgenic animals, most of the mutants that exhibit premature-
aging have mutations that disrupt normal gene function. It will be interesting to examine 
what is the result of overexpression of these components in mice and if this acts to promote 
longevity and delay aging. 
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Abstract 
Expression of p16Ink4a and p19Arf increases with age in both rodent and human tissues. 
However, whether these tumor suppressors are effectors of aging remains unclear, mainly 
because knockout mice lacking p16Ink4a or p19Arf die early of tumors. Here, we show that 
two tissues that develop early aging-associated phenotypes in response to BubR1 
insufficiency, skeletal muscle and fat, have high levels of p16Ink4a and p19Arf. Inactivation 
of p16Ink4a in BubR1 insufficient mice attenuates both cellular senescence and premature 
aging in these same tissues. Conversely, p19Arf inactivation exacerbates senescence and 
aging in BubR1 mutant mice. Thus, we identify BubR1 insufficiency as a trigger for 
activation of the Cdkn2a locus in certain mouse tissues, and demonstrate that p16Ink4a is an 
effector and p19Arf an attenuator of senescence and aging in these tissues.  
 
Introduction  
Cellular senescence is a state of irreversible growth arrest that can be induced by various 
cellular stressors1, 2. The Cdkn2a locus encodes two separate tumor suppressors, p16Ink4a, a 
cyclin-dependent kinase (Cdk) inhibitor that can block G1/S progression when present 
above a certain level, and p19Arf, a positive regulator of the transcription factor p53 that 
integrates and responds to a wide variety of cellular stresses1, 3-5. Both p16Ink4a and p19Arf 
are effectors of senescence in cultured cells6 and increase with aging in many tissues7, 8, 
leading to speculation that their induction is causally implicated in in vivo senescence and 
organismal aging. However, rigorous testing of this notion has been difficult because mice 
that lack p16Ink4a or p19Arf die of cancer long before they reach the age at which normal 
mice start to develop age-related disorders1, 2. Recent evidence in middle-aged p16Ink4a 
knockout mice indicates that the age-induced expression of p16Ink4a limits the proliferative 
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and regenerative capacity of progenitor populations9-11. Yet, whether increased stem-cell 
proliferation and tissue regeneration seen in p16Ink4a knockouts actually delays onset of 
age-related pathologies remains unknown due to the limited animal lifespan1, 12.  
 
One approach to study the role of p16Ink4a and p19Arf in aging would be to determine 
whether their respective inactivation in mouse models that develop aging-associated 
pathologies at an early age, due to single gene mutations, would prevent or delay premature 
aging. Mutant mice with low levels of the mitotic checkpoint protein BubR1 (called BubR1 
hypomorphic or BubR1H/H mice) undergo premature sister chromosome separation and 
develop progressive aneuploidy along with various progeroid phenotypes that include short 
lifespan, cachectic dwarfism, lordokyphosis (abnormal curvature of the spine), sarcopenia 
(age-related skeletal muscle atrophy), cataracts, craniofacial dysmorphisms, arterial 
stiffening, loss of (subcutaneous) fat, reduced stress tolerance and impaired wound 
healing13-15. During the course of natural aging, several mouse tissues show a dramatic 
decline in BubR1 protein expression, which, combined with the observation that BubR1H/H 
mice age prematurely, suggests a possible role for BubR1 in regulating natural aging13-15. 
Here we show that certain mouse tissues induce p16Ink4a and p19Arf in response to BubR1 
hypomorphism. Using BubR1H/H mice in which these tumor suppressors are lacking, we 
demonstrate that p16Ink4a is an effector of cellular senescence and aging, while, conversely, 
p19Arf acts to suppress cellular senescence and aging. 
 
Results 
 
p16Ink4a inactivation increases the lifespan of BubR1H/H mice 
To determine the requirement for p16Ink4a in the development of progeroid phenotypes in 
BubR1-insufficient mice, we bred BubR1H/H mice onto a p16Ink4a homozygous null genetic 
background. In total, 86 BubR1H/H/p16Ink4a–/–, 192 BubR1H/H, 160 BubR1+/+ and 44 p16Ink4a–
/– mice were generated and monitored for development of age-related phenotypes for a 
period of one year. Inactivation of p16Ink4a offered BubR1H/H mice a 25% extension of 
lifespan (Fig. 1a). Although the median lifespan of BubR1H/H mice was extended in the 
absence of p16Ink4a, the maximum lifespan was not, suggesting that the condition(s) that 
cause(s) death was not rescued by p16Ink4a inactivation.  
 
p16Ink4a loss blunts sarcopenia induced by BubR1 insufficiency 
A prominent aging-associated phenotype of BubR1H/H mice is the development of 
lordokyphosis13. The incidence of this phenotype was dramatically reduced in 
BubR1H/H/p16Ink4a–/– animals in comparison to BubR1H/H mice (Fig. 1b, c). Furthermore, the 
median time to onset of lordokyphosis was three times longer in BubR1H/H/p16Ink4a–/– mice 
than in BubR1H/H mice (Fig. 1b). Lordokyphosis is associated with both osteoporosis and  
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Figure 1 Ablation of p16Ink4a in BubR1H/H mice extends lifespan and attenuates sarcopenia. (a) Overall survival 
curves for wild-type, p16Ink4a–/–, BubR1H/H and BubR1H/H/p16Ink4a–/– mice. The median overall survival of combined 
BubR1H/H/p16Ink4a–/– mice is 25 weeks, a 25% extension in lifespan compared to BubR1H/H animals. We note that 
the p16Ink4a–/–, BubR1H/H and BubR1H/H/p16Ink4a–/– curves are all statistically different from the wild-type curve by 
log-rank tests (p < 0.0001). Moreover, the BubR1H/H/p16Ink4a–/– curve is statistically different from the BubR1H/H 
curve (p = 0.0142). (b) Incidence and latency of lordokyphosis in BubR1H/H and BubR1H/H/p16Ink4a–/– mice. The 
curves are statistically different by use of a log-rank test (p < 0.0001). We note that no wild-type or p16Ink4a–/– mice 
developed lordokyphosis during our one-year observation period (data not shown). (c) Images of 5-month-old 
wild-type, BubR1H/H and BubR1H/H/p16Ink4a–/– mice. Note the profound difference in the curvature of the spine in 
the BubR1H/H/p16Ink4a–/– mouse. (d) Cross sections of gastrocnemius muscles of 5-month-old wild-type, BubR1H/H, 
and BubR1H/H/p16Ink4a–/– mice. Arrowheads mark degenerated fibers and asterisks mark areas of connective tissue 
infiltration. Scale bar = 100 µm. (e) Quantitation of the number of deteriorating (atrophic) muscle fibers in 
gastrocnemius muscles shown in d. Note that BubR1H/H/p16Ink4a–/– muscles have three-fold less atrophic fibers than 
BubR1H/H muscles. Error bars are s.d. (f) Skinned 5-month-old wild-type, BubR1H/H and BubR1H/H/p16Ink4a–/– mice 
demonstrating that abdominal wall thickness is visually increased in BubR1H/H/p16Ink4a–/– mice when compared 
with BubR1H/H animals. 
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age-related degenerative loss of muscle mass and strength (sarcopenia) in wild-type mice 
of extremely advanced age16. Histological evaluation of longitudinal femur sections from 
kyphotic BubR1H/H mice revealed no evidence for osteoporosis (Supplementary 
Information, Fig. S1a, b). Histopathology on gastrocnemius and paraspinal muscles of 5-
month-old BubR1H/H mice, however, revealed clear signs of skeletal muscle atrophy and 
degeneration (Fig. 1d and data not shown). Muscle degeneration was greatly reduced in 
BubR1H/H muscles lacking p16Ink4a (Fig. 1d, e). In addition, abdominal muscles of BubR1H/H 
mice were poorly developed, as revealed by macroscopic analysis and magnetic resonance 
imaging (Fig. 1f and Supplementary Information, Fig. S1c). Depletion of p16Ink4a resulted 
in substantial correction of this defect. These data demonstrate that p16Ink4a plays a major 
role in establishing sarcopenia in BubR1H/H mice.  
 
p16Ink4a limits the regenerative capacity of beta cells and has been linked to pancreatic islet 
atrophy and development of diabetes9, 17, 18, which, in turn, can cause muscle atrophy 
through accelerated muscle protein degradation19. This prompted us to test whether the 
sarcopenia observed in BubR1H/H mice might be due to beta cell failure. BubR1H/H mice 
showed highly efficient glucose clearance in a glucose tolerance test (Supplementary 
Information, Fig. S2a). Complementary blood insulin measurements indicated that insulin 
sensitivity was not impaired in BubR1H/H mice and revealed no evidence for insulin 
resistance (Supplementary Information, Fig. S2b). Furthermore, overall pancreatic 
morphology as well as islet size, shape and abundance were similar in 12-month-old 
BubR1H/H and control mice, as verified by histology (Supplementary Information, Fig. 
S2c). Consistent with this, p16Ink4a expression in pancreas was not significantly elevated in 
BubR1H/H mice compared with BubR1+/+ counterparts (Fig. 3c). Thus, sarcopenia in 
BubR1H/H mice is unlikely to be the result of p16Ink4a-mediated beta cell degeneration or 
insulin resistance. 
 
BubR1 and p16Ink4a levels are inversely linked in skeletal muscle  
To determine if BubR1 might play a role in the normal skeletal muscle aging, we measured 
BubR1 protein levels in skeletal muscle of young and old wild-type mice by western blot 
analysis. Gastrocnemius muscles had considerably higher levels of BubR1 protein at two 
months than at 35 months of age (Fig. 2a and Supplementary Information, Fig. S6a). 
BubR1 transcripts were undetectable by quantitative (q)RT-PCR in the gastrocnemius of 
35-month-old mice but readily present at two months (data not shown), suggesting that 
reduced BubR1 transcriptional activity contributes to the decline in BubR1 protein levels at 
advanced age. In contrast to BubR1 transcription, p16Ink4a transcription dramatically 
increased with age in gastrocnemius muscles of old wild-type mice (Fig. 2b). 
Gastrocnemius of 2- and 5-month-old BubR1H/H mice also had high p16Ink4a transcript 
levels (Fig. 2b), providing evidence for an inverse relationship between BubR1 and p16Ink4a 
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Figure 2   Inverse correlation between BubR1 and p16Ink4a expression levels with aging. (a) Western blot analysis 
of gastrocnemius muscle in young wild-type and BubR1H/H mice and old wild-type mice. Blots were probed with 
antibodies against BubR1, Bub3 and Rae1. Anti-tubulin was used as a loading control. Note that the mitotic 
checkpoint proteins Bub3 and Rae1 remain highly expressed as wild-type mice age. Uncropped images of the 
scans are shown in Supplementary Information, Fig. S6a. (b) p16Ink4a expression in wild-type and BubR1H/H 
gastrocnemius muscles at various ages analyzed by qRT-PCR (n = 3 males per genotype and age group, with 
triplicate measurements taken). Values were normalized to GAPDH. Relative fold expression is to 2-month-old 
wild-type values. Error bars are s.d. (c) Myotube formation potential of gastrocnemius muscles from 5-month-old 
mice of the indicated genotypes analyzed by a well-standardized in vitro assay. Error bars are s.d. (d) Cardiotoxin 
treated gastrocnemius muscle of 5-month-old wild-type, BubR1H/H and BubR1H/H/p16Ink4a–/– mice at five days (top) 
or 18 days (bottom) after injection. Note that all gastrocnemius muscles exhibit an extensive hypercellular 
response to cardiotoxin injection by day 5 regardless of genotype. Wild-type and BubR1H/H/p16Ink4a–/– mice have 
complete restoration of muscle architecture by myofibers with central nuclei by day 18, while BubR1H/H mice have 
been unable to restore normal tissue structure. Scale bar = 100 µm. 
 
expression. To characterize this relationship further, we measured p16Ink4a expression in 
gastrocnemius of 3-week-old BubR1H/H mice, when skeletal muscle atrophy is 
histologically undetectable (Supplementary Information, Fig. S2d). p16Ink4a transcript 
levels were similarly elevated for 3-week-old, and 2- and 5-month-old mice (Fig. 2b), 
indicating that p16Ink4a induction is an early response to BubR1 hypomorphism that 
precedes histological signs of sarcopenia.  
 
Increased expression of p16Ink4a with age in adult stem cells is associated with reduced 
tissue repair and regeneration in several mouse tissues9-12. To explore whether p16Ink4a-
mediated exhaustion of myogenic stem cell potential might contribute to premature 
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sarcopenia in BubR1H/H mice, in vitro myoblast-to-myofiber differentiation assays were 
performed on gastrocnemius muscles from 5-month-old wild-type, BubR1H/H and 
BubR1H/H/p16Ink4a–/– mice. In these assays, the average number of myotubes obtained per 
milligram muscle tissue was about 7-fold lower in BubR1H/H mice than in wild-type mice 
(Fig. 2c). By contrast, only a 2-fold reduction in myotube formation was observed in 
BubR1H/H mice lacking p16Ink4a. To confirm these data, 5-month-old wild-type, BubR1H/H 
and BubR1H/H/p16Ink4a–/– mice were challenged to regenerate muscle fibers by injection of 
cardiotoxin, a sixty amino-acid polypeptide that causes acute injury by rapidly destroying 
muscle fibers20. Consistent with our in vitro data, muscle regeneration was overtly delayed 
in BubR1H/H mice, but not in BubR1H/H/p16Ink4a–/– counterparts (Fig. 2d). Collectively, these 
data indicate that p16Ink4a promotes sarcopenia in BubR1H/H mice, at least in part, by 
impairing muscle regeneration. 
 
p16Ink4a loss attenuates aging in selective BubR1 hypomorphic tissues 
Loss of p16Ink4a further caused a modest, yet significant, delay in the latency of cataract 
formation in BubR1H/H mice (Fig. 3a). Aged skin is characterized by reduced dermal 
thickness and subcutaneous adipose tissue, both of which are observed in BubR1H/H mice at 
young ages13. At two months of age, BubR1H/H, BubR1H/H/p16Ink4a–/–, and p16Ink4a–/– mice 
had similar amounts of subdermal adipose tissue (Fig. 3b). As expected, the mean 
thickness of the subcutaneous adipose layer notably decreased in 5-month-old BubR1H/H 
mice. This decline was not accompanied by increased fat storage in liver tissue 
(Supplementary Information, Fig. S2e). The decrease in subcutaneous fat was much less 
severe in age-matched BubR1H/H/p16Ink4a–/– mice (Fig. 3b), indicating that p16Ink4a is, at 
least in part, responsible for loss of subcutaneous adipose tissue in BubR1H/H mice. 
Tolerance of anesthetic stress was also greatly improved in BubR1H/H/p16Ink4a–/– mice 
(Supplementary Information, Table S1), as was adipose tissue deposition (Supplementary 
Information, Fig. S2f). However, several progeroid symptoms seen in BubR1H/H mice 
remained unchanged following loss of p16Ink4a, including dwarfism, dermis thinning, 
arterial wall stiffening, and infertility (Supplementary Information, Table S1 and data not 
shown). No progeroid phenotypes of BubR1H/H mice were aggravated by p16Ink4a loss. 
 
The differential corrective effects of p16Ink4a disruption on individual progeroid phenotypes 
infers tissue-specific differences in engagement of the p16Ink4a pathway in the cellular 
response to BubR1 deficiency. BubR1H/H tissues in which p16Ink4a loss causes a significant 
delay of premature aging, such as eye and (subdermal) adipose tissue, showed strong 
induction of p16Ink4a expression in response to BubR1 hypomorphism (Fig. 3c, d and 
Supplementary Information, Fig. S6b, c). BubR1H/H tissues in which p16Ink4a inactivation 
has no discernible corrective effect, such as dermis, brain, aorta, testis and ovary, did not 
exhibit significant p16Ink4a induction (Fig. 3c, and data not shown). Furthermore, mutant 
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tissues that are not subjected to premature aging, including lung, pancreas, colon and 
liver13, maintained low p16Ink4a expression levels. Together, these data demonstrate that 
p16Ink4a is activated in a subset of tissues in BubR1H/H mice, where it contributes to 
progeroid phenotypes.  
 
p16Ink4a loss attenuates in vivo senescence  
BubR1 is a putative E2F-regulated gene21 and loss of p16Ink4a leads to increased E2F 
transcriptional activity22. Accordingly, attenuation of aging in skeletal muscle, fat and eye 
might be the result of increased BubR1 gene expression. However, this is unlikely as 
BubR1 transcript levels in these tissues were not impacted by loss of p16Ink4a (Fig. 4a). As 
p16Ink4a is an effector of cellular senescence, p16Ink4a deletion might delay aging in 
hypomorphic mice by decreasing senescense. As shown in Fig. 4b, BubR1H/H adipose 
 
 
 
Figure 3   p16Ink4a disruption attenuates selective progeroid features of BubR1 hypomorphic mice. (a) Incidence 
and latency of cataract formation in BubR1H/H and BubR1H/H/p16Ink4a–/– mice as detected by the use of slit light 
after dilation of eyes. The curves are statistically different using a log-rank test (p < 0.0001). We note that no 
wild-type or p16Ink4a–/– mice developed cataracts during this observation period. (b) Subcutaneous adipose layer 
thickness of p16Ink4a–/–, BubR1H/H, and BubR1H/H/p16Ink4a–/– mice at two and five months of age (n = 4 male mice 
for each age per genotype). Error bars are s.d. A two-tailed Mann-Whitney test was used for statistical analyses 
(c) qRT-PCR analysis for relative expression of p16Ink4a in a variety of 2-month-old tissues from BubR1H/H and 
wild-type mice. Values were normalized to GAPDH, and relative fold is to 2-month-old wild-type samples (n = 
3 male mice for each tissue, with triplicate measurements taken). Error bars are s.d. (d) Western blots of eye 
and fat extracts from 2-month-old BubR1+/+ and BubR1H/H mice probed with anti-p16Ink4a antibody. Anti-tubulin 
antibody served as loading control. Uncropped images of the scans are shown in Supplementary Information, 
Fig. S6b, c. 
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Figure 4 p16Ink4a induction in BubR1H/H mice promotes cellular senescence. (a) Relative expression of BubR1 
in gastrocnemius, subdermal adipose, fat deposit, and eye from 2-month-old wild-type, p16Ink4a–/–, BubR1H/H and 
BubR1H/H/p16Ink4a–/– mice as determined by qRT-PCR. Values were normalized to GAPDH. Relative fold is to 2-
month-old wild-type samples (n = 3 male mice per genotype, with triplicate measurements taken per sample). 
Error bars are s.d. We note that ablation of p16Ink4a was unable to increase the amount of BubR1 present in 
either wild-type or BubR1 hypomorphic mice. (b) IAT of 5-month-old wild-type, BubR1H/H and 
BubR1H/H/p16Ink4a–/– mice stained for SA-beta-galactosidase activity. (c) Relative expression of senescence 
markers in gastrocnemius muscles of 2-month-old wild-type, p16Ink4a–/–, BubR1H/H and BubR1H/H/p16Ink4a–/– mice 
analyzed by qRT-PCR (n = 3 male mice per genotype). Values were normalized to GAPDH. Relative fold 
expression is to 2-month-old wild-type muscle. Error bars are s.d. (d) Analysis of replicative senescence in 
skeletal muscle and fat of 2-month-old wild-type, BubR1H/H and BubR1H/H/p16Ink4a–/– mice by analyzing in vivo 
BrdU incorporation (n = 3 males per genotype). Error bars are s.d. 
 
tissue expresses high levels of senescence-associated (SA) beta-galactosidase, a marker of 
cellular senescence23. SA-beta-galactosidase staining was much lower in adipose tissue of 
BubR1H/H/p16Ink4a–/– mice (Fig. 4b). Skeletal muscles of 2-month-old BubR1H/H mice did 
not stain positive for SA-beta-galactosidase but expressed high levels of several other 
senescence-associated genes, including Igfbp2, Nrg1, Mmp13 and PAI-124-27 (Fig. 4c). 
Expression of these markers was markedly decreased in skeletal muscles of age-matched 
BubR1H/H/p16Ink4a–/– mice. A key feature of senescence is loss of proliferative potential. In 
vivo 5-bromo-2-deoxyuridine (BrdU) labeling showed that 2-month-old BubR1H/H mice 
had much lower percentages of cycling cells in skeletal muscle and fat than wild-type mice 
(Fig. 4d). These reductions were less profound in BubR1H/H/p16Ink4a–/– mice. Collectively, 
these data suggest that BubR1 hypomorphism causes cellular senescence in adipose tissue 
and skeletal muscle through a p16Ink4a-dependent mechanism. As p16Ink4a inactivation 
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Figure 5 p19Arf is elevated in BubR1 hypomorphic tissues with high p16Ink4a. (a) Skeletal muscles of wild-type 
and BubR1H/H mice of various ages were analyzed for p19Arf expression by qRT-PCR. All values were normalized 
to GAPDH. Three mice were used per genotype and age group. Error bars are s.d. (b) Relative expression of p19Arf 
in various tissues of 2-month-old BubR1H/H and BubR1+/+ mice as measured by qRT-PCR (n = 3 males per 
genotype). All values were normalized to GAPDH. Relative expression is to wild-type samples. Error bars are s.d. 
(c) Western blots of eye and fat extracts from 2-month-old BubR1+/+ and BubR1H/H mice probed with anti-p19Arf and 
p15Ink4b antibodies. Anti-tubulin antibody served as loading control. Uncropped images of the scans are shown in 
Supplementary Information, Fig. S6b, c. (d) Relative expression of p19Arf in skeletal muscle (gastrocnemius), 
subdermal adipose, fat deposit, and eye of 2-month-old wild-type, BubR1H/H and BubR1H/H/p16Ink4a–/– mice as 
determined by qRT-PCR (n = 3 males per genotype). All values were normalized to GAPDH. Relative expression 
is to wild-type samples. Error bars are s.d. 
 
 
attenuates both senescence and aging in these tissues, the mechanism by which BubR1 
hypomorphism accelerates the aging phenotypes may involve p16Ink4a-induced senescence.  
 
p19Arf is elevated in BubR1H/H tissues with high p16Ink4a  
Besides p16Ink4a, p19Arf is expressed at increased levels in many tissues of wild-type mice 
with advanced age7, including skeletal muscle (Fig. 5a). Although p19Arf is an established 
effector of senescence in cultured MEFs, its role in senescence and aging in the context of 
the whole organism has not been clarified1, 2. To explore the role of p19Arf in BubR1-
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mediated aging, we analyzed its relative expression in tissues from 2-month-old BubR1H/H 
and BubR1+/+ mice. Increased p19Arf expression was consistently observed in BubR1H/H 
tissues that are subjected to premature aging and have high p16Ink4a levels, including 
skeletal muscle, (subdermal) adipose and eye, but not in tissues that develop age-related 
pathology in a p16Ink4a-independent fashion or have no age-related phenotypes (Fig. 5b, c 
and Supplementary Information, Fig. S6b, c and data not shown). Skeletal muscle, 
(subdermal) adipose and eye from BubR1H/H mice lacking p16Ink4a had normal p19Arf 
transcript levels (Fig. 5d), suggesting that the observed increase in p19Arf expression is 
dependent on high p16Ink4a levels. p15Ink4b, encoding a Cdk inhibitor that has been linked to 
aging in some tissues7, was neither increased in BubR1H/H tissues with increased p16Ink4a 
and p19Arf expression, nor in any other tissue of BubR1H/H mice (Supplementary 
Information, Fig. S3a and Fig. S6b, c). Unlike p16Ink4a and p19Arf, p15Ink4b was not 
expressed at increased levels in skeletal muscles of aged wild-type mice (Supplementary 
Information, Fig. S3b).  
 
p19Arf disruption accelerates aging in BubR1H/H mice 
To determine whether p19Arf also acts as an effector of aging in BubR1H/H mice, 41 
BubR1H/H/p19Arf–/– mice were generated and monitored for development of age-related 
phenotypes. Surprisingly, lordokyphosis developed significantly faster in BubR1H/H/p19Arf–
/– mice than in BubR1H/H mice (Fig. 6a and b). Six-week-old BubR1H/H/p19Arf–/– mice had 
significantly smaller fibers in gastrocnemius and abdominal muscles than age-matched 
BubR1H/H mice (Fig. 6c and Supplementary Information, Fig. S4a), indicating that muscle 
wasting was accelerated in the absence of p19Arf. Cataract formation was also significantly 
accelerated when p19Arf was lacking (Fig. 6d). Skinned 6-week-old BubR1H/H/p19Arf–/– mice 
showed overt reductions in adipose tissue deposition (Fig. 6b). This was confirmed by 
weighing inguinal adipose tissue (IAT, Fig. 6e). Furthermore, the mean thickness of the 
subcutaneous adipose layer was significantly smaller in BubR1H/H/p19Arf–/– mice than in 
BubR1H/H mice (0.07 versus 0.11 mm; p < 0.0001 using a two-tailed Mann-Whitney test). 
Other progeroid features of BubR1H/H mice appeared unchanged by p19Arf inactivation 
(Supplementary Information, Fig. S4b and Table S1). Taken together, these data indicate 
that p19Arf acts to delay aging in response to BubR1 hypomorphism.  
 
One possible explanation for the pro-aging effect of p19Arf inactivation in BubR1H/H mice 
might involve increased expression of p16Ink4a. Consistent with this idea, p16Ink4a levels in 
skeletal muscle, fat and eye markedly increased when p19Arf was knocked out in BubR1H/H 
mice (Fig. 6f, g and Supplementary Information, Fig. S6d). A potential explanation for 
these results might be that genetic manipulation of p19Arf sequences changes the normal 
regulatory balance in the Cdkn2 locus, thereby increasing p16Ink4a expression. However, 
disruption of p19Arf had no appreciable effect on p16Ink4a levels in tissues undergoing  
 119 
 
 
Figure 6 Accelerated aging in BubR1H/H mouse tissues with increased p16Ink4a expression when p19Arf is lacking. 
(a) Incidence and latency of lordokyphosis in BubR1H/H and BubR1H/H/p19Arf–/– mice. The curves are statistically 
different by use of a log-rank test (p < 0.0001). (b) Skinned 6-week-old BubR1H/H and BubR1H/H/p19Arf–/– males. 
Note that the BubR1H/H/p19Arf–/– mouse has more profound lordokyphosis (dotted line) and reduced subcutaneous 
fat deposits (arrows).  (c) Average muscle fiber size of gastrocnemius and abdominal muscles of BubR1H/H and 
BubR1H/H/p19Arf–/– males (n = 3 mice per genotype). Error bars are s.d. A two-tailed Mann-Whitney test was used 
for statistics. P values for both comparisons are < 0.0001. (d) Incidence and latency of cataract formation in 
BubR1H/H and BubR1H/H/p19Arf–/– mice. The curves are statistically different as calculated by a log-rank test (p < 
0.0001). (e) Amount of inguinal adipose tissue in 6-week-old mice of the indicated genotypes. IAT is expressed as 
percentage of total body weight. Three male mice of each genotype were used. (f) Western blots of eye and fat 
extracts from 2-month-old BubR1H/H and BubR1H/H/p19Arf–/– mice probed with anti-p16Ink4a and anti-tubulin 
antibody. Uncropped images of the scans are shown in Supplementary Information, Fig. S6d. (g) Relative 
expression of p16Ink4a in various tissues of 2-month-old BubR1+/+, BubR1H/H and BubR1H/H/p19Arf–/– mice as 
measured by qRT-PCR (n = 3 males per genotype). All values were normalized to GAPDH. Relative expression is 
to wild-type samples. Error bars are s.d. 
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p16Ink4a-independent aging or lacking age-related pathologies (Fig. 6g), which argues 
against this possibility.  
 
Inactivation of p19Arf increases cellular senescence 
Next, we investigated whether p19Arf loss accelerates aging in BubR1H/H mice through 
increased senescence. Adipose tissue of 6-week-old BubR1H/H/p19Arf–/– mice indeed showed 
 
 
Figure 7 Senescence increases in BubR1H/H tissues with high p16Ink4a when p19Arf is lacking. (a) IAT of 2-
month-old BubR1H/H and BubR1H/H/p19Arf–/– mice stained for SA-beta-galactosidase activity. (b) Relative 
expression of senescence markers in gastrocnemius muscles of 6-week-old wild-type, p19Arf–/–, BubR1H/H and 
BubR1H/H/p19Arf–/– mice. All values were normalized to GAPDH. Relative fold expression is to wild-type 
gastrocnemius. Three male mice were evaluated per genotype. Error bars are s.d. (c) Replicative senescence in 
skeletal muscle and fat of 2-month-old wild-type, BubR1H/H and BubR1H/H/p19Arf–/– mice as analyzed by in vivo 
BrdU incorporation. Three male mice per genotype were used for this experiment. Error bars are s.d. 
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much higher SA-beta-galactosidase activity than that of corresponding BubR1H/H mice (Fig. 
7a). Furthermore, two senescence-associated genes, Igfbp2 and Nrg1, which are expressed 
at increased levels in gastrocnemius muscles of 6-week-old BubR1H/H mice, were further 
elevated in corresponding muscles of age-matched BubR1H/H/p19Arf–/– mice (Fig. 7b). In 
vivo BrdU incorporation showed that cell proliferation in skeletal muscle and fat was 
considerably lower in BubR1H/H/p19Arf–/– mice than in BubR1H/H mice (Fig. 7c). 
Collectively, these data indicate that p19Arf induction in BubR1H/H mice functions to prevent 
or delay senescence and provide further evidence for the notion that in vivo senescence 
promotes aging.  
 
Distinct in vivo and in vitro effects of p16Ink4a and 19Arf inactivation on senescence 
Previously, we have shown that BubR1H/H MEFs express high p16Ink4a and p19Arf levels and 
senesce early13. To determine the effects p16Ink4a and p19Arf on cellular senescence in these 
MEFs, we stained BubR1H/H/p16Ink4a–/– and BubR1H/H/p19Arf–/– MEFs for SA-beta-
galactosidase. Inactivation of p19Arf strongly decreased senescence in BubR1H/H MEFs, 
whereas inactivation of p16Ink4a had no effect (Supplementary Information, Fig. S5a, b). 
Consistently, the percentage of cycling cells was greatly increased in BubR1H/H/p19Arf–/– 
MEFs, but not in BubR1H/H/p16Ink4a–/– MEFs (Supplementary Information, Fig. S5c, d). 
Furthermore, BubR1H/H/p19Arf–/– MEFs grew considerably faster than BubR1H/H MEFs, but 
BubR1H/H/p16Ink4a–/– MEFs did not (Supplementary Information, Fig. S5e, f). 
Immunoblotting showed that the p19Arf-p53 pathway remained highly active in 
BubR1H/H/p16Ink4a–/– MEFs, similar to BubR1H/H MEFs, while it was inactive in 
BubR1H/H/p19Arf–/– MEFs (Supplementary Information, Fig. S5h, g). Together, these data 
demonstrate that the effects of p16Ink4a and 19Arf ablation on in vivo senescence in skeletal 
muscle and fat of BubR1H/H mice are not recapitulated by their effects on in vitro 
senescence in BubR1H/H MEFs. 
 
p16Ink4a loss synergizes with BubR1 insufficiency in lung tumorigenesis  
BubR1H/H mice exhibit progressive and severe aneuploidy but rarely develop tumors13. 
Activation of p16Ink4a or p19Arf in response to BubR1 hypomorphism might act to suppress 
tumorigenesis. To test for this possibility, BubR1H/H mice lacking p16Ink4a or p19Arf were 
monitored for tumor formation. Live BubR1H/H/p16Ink4a–/– and BubR1H/H mice showed no 
overt tumors, but upon biopsy of moribund or dead animals, BubR1H/H/p16Ink4a–/– mice had 
significantly more tumors than BubR1H/H mice (Fig. 8a). Eight out of nine 
BubR1H/H/p16Ink4a–/– tumors were lung adenocarcinomas, a tumor type observed in only one 
BubR1H/H mouse and zero p16Ink4a–/– mice (Fig. 8b). Sarcomas, the most prevalent tumor 
type in p16Ink4a–/– mice, were rare in BubR1H/H/p16Ink4a–/– mice and not present in BubR1H/H 
mice. Thus, BubR1 insufficiency synergizes with p16Ink4a loss during tumorigenesis in lung 
epithelial cells, but not in other cell types (see Supplementary Discussion). 
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BubR1H/H/p19Arf–/– and p19Arf–/– mice, however, had overlapping tumor-free survival curves 
(Fig. 8c), indicating that BubR1 insufficiency and p19Arf loss do not synergize in 
tumorigenesis. 
 
 
Figure 8 Ablation of p16Ink4a accelerates lung tumorigenesis in BubR1 insufficient mice. (a) Percentage of 
mice which had a tumor at time of death as a function of time for p16Ink4a–/–, BubR1H/H and BubR1H/H/p16Ink4a–/– 
mice. Upon biopsy of moribund animals, all tissues were screened for tumors. Tumor tissues were collected and 
processed for histological confirmation. The BubR1H/H/p16Ink4a–/– curve is statistically different from the BubR1H/H 
curve with p = 0.0027 (calculated using a log-rank test). (b) Tumor spectra of p16Ink4a–/–, BubR1H/H and 
BubR1H/H/p16Ink4a–/– mice. (c) As in a but now for p19Arf–/–, BubR1H/H and BubR1H/H/p19Arf–/– mice. There is no 
statistical difference between the curves of BubR1H/H/p19Arf–/– and p19Arf–/– mice using a log-rank test. 
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Discussion 
 
Here, we report that inactivation of p16Ink4a attenuates the development of age-related 
pathologies in BubR1H/H tissues with elevated p16Ink4a. This shows that induction of p16Ink4a 
by cellular stress resulting from BubR1-insufficiency drives the development of aging-
associated phenotypes, and provides direct evidence for a causal involvement of this tumor 
suppressor in organismal aging. Importantly, two tissues that are subject to p16Ink4a-
dependent aging when BubR1 levels are low, skeletal muscle and fat, have higher numbers 
of replicating cells and show decreased expression of senescence-associated proteins in the 
absence of p16Ink4a. These observations support the notion that p16Ink4a contributes to 
aging-associated pathologies through accumulation of senescent cells. This is a significant 
finding as evidence that cellular senescence promotes aging has thus far been largely 
circumstantial2, 6. 
 
BubR1H/H mouse tissues in which p16Ink4a is elevated also have increased p19Arf. However, 
p19Arf inactivation accelerates instead of delays aging in these tissues, indicating that this 
tumor suppressor provides anti-aging activity. This seems surprising, considering that 
p19Arf is an effector of senescence in cultured cells2, 6. However, the recent observation that 
transgenic mice carrying an extra copy of both p19Arf and p53 are protected from aging-
associated damage and live longer than normal mice28, is consistent with our finding that 
p19Arf has anti-aging activity in BubR1H/H mice. It has been proposed that the p19Arf-p53 
pathway in response to low, chronic stress, may primarily induce genes that promote cell 
survival and repair, thereby extending lifespan5, 28, 29. High, acute kinds of stress, on the 
other hand, may accelerate aging by triggering a more robust p53 response causing 
irreversible cell-cycle arrest and/or apoptosis5, 29-31. Therefore, one possibility is that p19Arf 
may elicit a p53 transcriptional response that provides protection against cellular stress 
resulting from BubR1 hypomorphism, thus delaying the onset of cellular senescence. The 
observation that skeletal muscle and fat from BubR1H/H mice lacking p19Arf accumulate 
more senescent cells is consistent with this idea. Strong additional support for the 
conclusion that p19Arf has anti-aging activity is provided by our unpublished observations 
indicating that BubR1H/H mice lacking p53 phenocopy those lacking p19Arf. Two 
observations reported here suggest that p19Arf might exert its anti-aging effect, at least in 
part, through negative regulation of p16Ink4a expression. First, inactivation of p19Arf in 
BubR1H/H mice resulted in increased p16Ink4a expression in skeletal muscle, fat and eye, 
three tissues that have high p19Arf levels and are subjected to accelerated aging. Second, 
inactivation of p16Ink4a prevented the induction of p19Arf in these same BubR1H/H tissues. 
How p19Arf might attenuate p16Ink4a expression remains to be addressed.    
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Although inactivation of p16Ink4a significantly delays the development of certain aging-
associated phenotypes in BubR1H/H mice, it does not completely prevent them. 
Furthermore, other progeroid phenotypes are not impacted by loss of p16Ink4a. These 
findings imply that BubR1 hypomorphism engages other progeroid effectors in addition to 
p16Ink4a. The identity of these effectors is currently unclear and remains to be established. 
Striking similarities exist between the progeroid phenotypes of BmalI knockout and 
BubR1H/H mice32. The molecular basis of this similarity is unclear, although it is unlikely, 
based on the known functions of each protein, that BubR1 and BmalI are functionally 
connected. However, it is possible that the downstream pathways that respond to stress 
resulting from Bmal1 loss and BubR1 hypomorphism are shared. 
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Methods 
 
Generation of compound mutant mice 
BubR1H/H mice were generated as previously described13. p16Ink4a and p19Arf knockout mice 
have been previously generated and were acquired from the Mouse Models of Human 
Cancers Consortium located at the National Cancer Institute-Frederick33, 34. All mice were 
on a mixed 129 x C57BL/6 genetic background. They were housed in a pathogen-free 
barrier environment throughout the duration of the study. Experimental procedures 
involving the use of these laboratory mice were reviewed and approved by the Institutional 
Animal Care and Use Committee of the Mayo Clinic. Prism software (GraphPad Software, 
Inc.) was used for generation of all survival curves and for statistical analyses. 
 
Collection and analysis of tumors 
Moribund mice were killed and all major organs were screened for overt tumors using a 
dissection microscope. Tumors that were collected were processed by standard procedures 
for histopathology. A Fisher’s exact test was used to compare tumor incidence proportions 
across the genotypes for mice that developed tumors. Board-certified pathologists assisted 
in the histological evaluation of tumor sections. 
 
Analysis of progeroid phenotypes  
Biweekly, mice were screened for the development of overt cataracts by examining dilated 
eyes with a slit-light. Incidence of lordokyphosis was checked biweekly. Mice that 
exhibited lordokyphosis for three consecutive monitoring periods were determined to have 
this condition. Various skeletal muscles were collected and processed for histology as 
described35, 36. Fiber diameter measurements were done on cross sections of gastrocnemius 
and abdominal muscles from 6-week-old male mice (n = 3 mice per genotype). A total of 
50 fibers were measured per muscle using a calibrated computer program (Olympus 
MicroSuite Five). Dissection, histology and measurements of dermal and adipose layers of 
dorsal skin were performed as described16. Values represent an average of four males. 
Analysis of arterial wall stiffening was performed as described14. Measurements of body 
weight and IAT were performed on 6-week-old males (n = 3 per genotype). Oral glucose 
tolerance tests were performed on 5-month-old male mice (n = 5 per genotype) as 
described by the Jackson Laboratory (www.jax.org). Insulin measurements were as 
described37. 
 
Quantitative real-time PCR 
Total RNA was extracted from tissues using a Qiagen RNeasy RNA isolation kit according 
to the manufacturer’s protocol. Transcription into cDNA was performed using random 
hexamers and SuperScript III reverse transcriptase (Invitrogen Corp.) according to 
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manufacturer’s instructions. All PCR reactions used SYBR green PCR Master Mix 
(Applied Biosystems) to a final volume of 12 µl, with each cDNA sample performed in 
triplicate in the ABI PRISM 7900 Sequence Detection System (Applied Biosystems) 
according to the protocol of the manufacturer. All experiments were done on organs/tissues 
from at least three different animals in each age group and genotype.  The expression of 
genes was normalized to GAPDH. Sequences of primers used for qRT-PCR of p15Ink4b 38, 
p16Ink4a 39, p19Arf 28, BubR140, Mmp-1341, PAI-142,  Igfbp-243, and GAPDH44 were as 
published. Additionally, sequences for Nrg1: forward, 
CATGGTGAACATAGCGAATGGCC; reverse, CCACAATATGCTCACTGGAGATG 
A. Statistical differences were determined by using an un-paired two-tailed t test. 
 
Analysis of satellite cell function 
Analyses of in vivo satellite cell function were carried out as described20. Briefly, 
anesthetized mice were given a single 50-µl injection of cardiotoxin (10 µM; Calbiochem, 
San Diego, CA) into the gastrocnemius muscle. After this injection, the skin incision was 
closed with a nylon suture. Mice were allowed to recover and then were analyzed at both 5 
and 18 days post-injection by routine histology. Isolation and culture of skeletal muscle 
satellite cells was performed as described45. Briefly, hind-limb muscles of 5-month-old 
mice were removed and trimmed of excess connective tissue and fat. Minced muscles were 
subjected to several 15-min rounds of digestion at 37ºC in incubation medium (50% 
DMEM high glucose (GIBCO)/50% F-12K (CellGro)/168U/mL collagenase type II 
(Worthington)/0.04% Trypsin (GIBCO)). Once fully digested, cells were successively 
filtered through 70 and 40 µm strainers, collected by centrifugation at 300 x g for 5 min 
and resuspended in propagation medium (DMEM high glucose/15% FCS 
(GIBCO)/glutamine (CellGro)/penicillin-streptomycin (CellGro)). After seven days in 
culture, differentiation medium (propagation medium with 2% FCS) was applied and cells 
were fixed seven days after the switch in medium. Myotube formation was quantified using 
the total number of myotubes for each sample normalized to the muscle mass extracted. 
 
Magnetic resonance imaging  
Magnetic resonance images with a 7-tesla scanner (Bruker, Billerica, MA) were obtained 
in 2%-isofluorane anesthetized mice using a spin-echo method as previously described46. 
Digital images were analyzed with the Metamorph software (Visitron, Universal Imaging, 
Downingtown, PA). The ratio of muscle area (paraspinal and chest or abdominal wall 
muscles) to total body cross-section was measured at the distal thorax and mid-abdomen 
levels.  
 
In vivo BrdU incorporation 
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At 24 and 6 h before tissue collection, male mice of various genotypes were injected 
intraperitoneally with 200 µl of 10 mg/ml BrdU (Sigma) in PBS. Mice were anesthetized 
and successively perfused (transcardially) with PBS and 10% formalin. Organs were 
collected and embedded in paraffin. Five µm sections were prepared and stained for BrdU 
according to the manufacturer’s protocol (BD Pharmingen). The percentage of BrdU 
positive cells was determined by counting total and BrdU positive nuclei in 10 non-
overlapping fields at 40-x magnification. N = 3 mice per genotype. 
 
Generation and culture of MEFs 
MEFs were generated as described47. BrdU incorporation assays on MEFs were performed 
according to the protocol of the manufacturer (BD Bioscience). Growth curves were 
generated as described13. Three independent MEF lines for each genotype were analyzed in 
both experiments. 
 
SA-beta-galactosidase staining 
Adherent MEFs were stained with a SA-beta-galactosidase activity kit according to 
manufacturer’s protocol (Cell Signaling). Nuclei were stained with Hoechst to determine 
percentages of cells positive for SA-beta-galactosidase activity. The percentage of SA-
beta-galactosidase-positive cells was the total number of cells positive for SA-beta-
galactosidase activity divided by the total number of cells (n = 3 independent MEF lines for 
each genotype at each passage). Adipose tissue depositions were stained for SA-beta-
galactosidase activity as described previously13. 
 
Western blot analysis 
Western-blot analyses were carried out as described48. Antibodies for senescence-
associated proteins were as described13, 16. Antibody for p15Ink4b was a gift from Dr. M. 
Barbacid49. 
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Supplementary Discussion 
 
The only discernible adverse effect of p16Ink4a inactivation in BubR1 hypomorphic mice 
was an acceleration of lung tumorigenesis. The simplest explanation for this effect would 
be that p16Ink4a is induced in BubR1 hypomorphic lung tissue as part of a tumor-
suppressive mechanism triggering senescence of cells that are at risk for neoplastic 
transformation. We extensively screened BubR1 hypomorphic lungs for the presence of 
premalignant lesions, but none were found (data not shown). This precluded us from 
testing whether p16Ink4a levels are indeed elevated in such lesions. Alternatively, as 
aneuploidy has been shown to promote tumorigenesis in certain mouse tissues1, it is 
conceivable that the numerical chromosome instability resulting from BubR1 insufficiency 
cooperates with p16Ink4a loss in lung tumorigenesis. Our data demonstrating that p16Ink4a 
inactivation accelerates lung tumorigenesis in BubR1 hypomorphic mice provides a first 
example of synergy between a mitotic checkpoint gene defect and a cancer gene mutation. 
Our observation that BubR1 insufficiency does not cooperate with p19Arf loss in 
tumorigenesis, suggests that the genetic context or microenvironment in which mitotic 
checkpoint gene defects promote tumorigenesis is limited. 
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Figure S1   Screening of BubR1+/+ and BubR1H/H mice for osteoporosis and analysis of BubR1+/+, BubR1H/H 
and BubR1H/H/p16Ink4a–/– mice for abdominal muscle volume and fat disposition. (a) Haematoxylin and eosin-
stained longitudinal sections of femurs from a 1-year-old wild-type, a 1-year-old BubR1 hypomorphic and a 
35-month-old wild-type mouse. Scale bar = 100 µm. (b) Quantitation of relative width of the cortical wall to 
total bone width in sections from a. For each genotype, three male mice were used and 40 random 
measurements were taken. Note the clear reduction in bone mass and density in the old wild-type animal, 
while there is no difference between the 1-year-old samples. Asterisks indicates p value of < 0.0001 
compared to 12-month-old wild-type using a two-tailed Mann-Whitney test. Error bars are s.d. (c) Analysis 
of abdominal muscle and fat tissue of 5-month-old wild-type, BubR1H/H, and BubR1H/H/p16Ink4a–/– mice by 
MRI. Representative cross-sectional MRI images are shown. Areas of muscle (M), fat (F), and the spinal 
cord (S) are indicated. Note the substantial increase in fat and muscle in BubR1H/H/p16Ink4a–/– mice. 
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Figure S2   Analysis of pancreatic beta-cell function, young skeletal muscle histology, and fat deposition 
of BubR1 hypomorphic mice (a-c) BubR1 hypomorphic mice have normal pancreatic beta-cell function. 
Changes in blood glucose (a) and insulin (b) levels after oral glucose administration to 5-month-old 
BubR1+/+ and BubR1H/H mice (n = 5 males for each genotype). Error bars are s.d. (c) Hematoxylin and eosin 
stained pancreas sections of 1-year-old BubR1+/+ and BubR1H/H mice. Arrowheads mark beta-cell islets. 
Scale bar = 100 µm. (d) Muscles of 3-week-old BubR1H/H appear normal. Cross-sections of gastrocnemius 
muscles from 3-week-old wild-type and BubR1H/H mice stained with hematoxylin and eosin. Scale bar = 
100 µm. (e) BubR1 hypomorphic mice do not have fatty livers. Hematoxylin and eosin stained liver 
sections of 5-month-old BubR1+/+ and BubR1H/H mice. Scale bar = 100 µm. (f) Quantitation of inguinal 
adipose tissue in 6-week-old BubR1+/+, BubR1H/H and BubR1H/H/p16Ink4a–/– mice. IAT is expressed as 
percentage of total body weight. Three males of each genotype were used. Note that BubR1H/H mice lacking 
p16Ink4a have improved fat disposition.  
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Figure S3    p15Ink4b is not induced in response to BubR1 hypomorphism. (a) Relative expression of 
p15Ink4b in different tissues of 2-month-old BubR1H/H and BubR1+/+ mice as determined by qRT-PCR (n = 
3 males for each genotype). All values were normalized to GAPDH. Relative expression is to wild-type 
samples. Error bars are s.d. (b) Relative expression of p15Ink4b in gastrocnemius muscles of wild-type and 
BubR1H/H males at various ages as measured by qRT-PCR (n = three muscles per genotype and age 
group). Values were normalized to GAPDH. Relative fold expression is to 2-month-old wild-type values. 
Error bars are s.d. 
 
 
 
 136 
 
 
Figure S4   Ablation of p19Arf in BubR1 hypomorphic mice increases muscle wasting but has no 
impact on lifespan. (a) Cross sections of gastrocnemius and abdominal muscles from 6-week-old 
BubR1H/H and BubR1H/H/p19Arf–/– mice. Sections were stained with hematoxylin and eosin. Note that 
fibers diameters are typically smaller when p19Arf is lacking. Scale bar = 100 µm. (b) Overall survival 
curves for wild-type, p19Arf–/–, BubR1H/H, and BubR1H/H/p19Arf–/– mice. We note that BubR1H/H and 
BubR1H/H/p19Arf–/– curves are not statistically different using a log-rank test. 
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Figure S5   In vivo and in vitro effects of p16Ink4a and 19Arf ablation on cellular senescence are dissimilar.  (a 
and b) Percentages of SA-beta-galactosidase positive cells in P3, P5 and P7 MEF cultures of the indicated 
genotypes. For each genotype and passage, three independent MEF lines were scored for SA-beta-
galactosidase staining. Error bars are s.d. (c and d) Percentages of cycling cells in P7 MEF cultures of the 
indicated genotypes as measured by BrdU incorporation. Three independent MEF lines were used for each 
genotype. Error bars are s.d. (e and f) In vitro growth curves of P7 MEF cultures of the indicated genotypes. 
On day 0, 1.5 x 105 cells were seeded in duplicate and counted for five consecutive days thereafter in three 
independent lines of each genotype. Compared to wild-type MEFs, the proliferative capacity of both BubR1H/H 
and BubR1H/H/p16Ink4a–/– MEFs was greatly reduced but that of BubR1H/H/p19Arf–/– was not. Lines represent three 
independent MEF lines per genotype. Error bars are s.d. (g) Western blots of extracts from P7 MEFs of the 
indicated genotypes probed for p16Ink4a, p19Arf, p53 and p21. Extracts from three independent MEF lines (1-3) 
were loaded for each genotype. (h) Western blots of extracts from P3, P5, and P7 MEFs of the indicated 
genotypes were probed for p16Ink4a, p19Arf, p53 and p21. Blots are representative of three independent MEF 
lines of each genotype. Actin was used as a loading control.  
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Figure S6   Uncropped images of the western blots shown in: (a) Fig. 2a, (b and c) Fig. 3d and Fig. 5c, (d) 
Fig. 6f. Blots were cut horizontally into two portions prior to antibody incubations. Arrowheads indicate 
specific bands shown in cropped images. 
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Summary 
 
BubR1 is a mitotic checkpoint protein that is mutated or expressed at reduced levels in a 
variety of human cancers. In our initial studies we sought to answer two main questions: 
First, does BubR1 insufficiency in mice cause chromosome missegregation and 
accumulation of aneuploid cells? What is the biologically critical role of BubR1? Data 
from experiments designed to answer these initial questions led us to pose several new 
questions: Is BubR1’s role in suppression of cancer and aging unique or shared by other 
mitotic checkpoint proteins? Do BubR1 and other mitotic checkpoint proteins have 
functions outside of their roles in mediating the metaphase to anaphase transition during 
mitosis?  
 
To clarify the physiological relevance of BubR1, we generated a series of mice in which 
protein levels gradually decreased from normal to zero by using BubR1 hypomorphic and 
knockout alleles (Chapter 3). BubR1-null mice were not obtained, demonstrating that 
BubR1 is required for normal development. However, hypomorphic BubR1 mice, which 
express approximately 10% of normal BubR1 protein, were liveborn and able to develop to 
adulthood. Cells from these mice are unable to segregate their chromosomes with high 
fidelity and accumulate more and more aneuploid cells as they mature. Despite vast 
amounts of aneuploidy, these mice rarely develop spontaneous tumors. However, 
challenging these animals with carcinogens resulted in nearly 3-fold more tumors, 
indicating that BubR1 acts to reduce the risk of neoplastic transformation. Additionally, 
these mice develop a wide array of early aging-associated phenotypes, including reduced 
lifespan, cachetic dwarfism, lordokyphosis, muscle atrophy, cataracts, loss of subcutaneous 
adipose tissue, and impaired wound healing. Follow-up studies revealed that BubR1 
hypomorphic animals had arterial walls that were thin and contained only small amounts of 
vascular smooth muscle cells, causing arterial stiffening and fibrosis, a hallmark of aging in 
humans (Chapter 4). This, combined with the observation that BubR1 levels decline in 
several tissues with age in normal mice, led us to propose that BubR1 is a regulator of 
natural aging.  
 
Because we propose that BubR1 regulates natural aging, we investigated the relationship 
between BubR1 and other genes thought to contribute to aging. p16Ink4a or p19Arf are two 
proteins whose expression goes up with age in many tissues of normal wild-type mice [1]. 
We also observed that these two proteins are expressed at increased levels in certain tissues 
of BubR1 hypomorphic mice (Chapter 5). We then tested if p16Ink4a or p19Arf mediated the 
age-related pathology of BubR1 hypomorphic mice by ablating them. We found that 
disruption of p16Ink4a in hypomorphic BubR1 mice results in a delayed onset of age-related 
pathology in tissues that express p16Ink4a at higher than normal levels, including skeletal 
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muscle, (subdermal) fat and eye. The observed delay in muscle and adipose tissue aging 
was coupled with a reduction in cellular senescence in these tissues. Interestingly, when we 
ablate p19Arf in hypomorphic BubR1 animals, all tissues that have this protein elevated 
exhibit an earlier onset of age-related disease, including increased rates of cellular 
senescence. Together, these data demonstrate that in hypomorphic BubR1 mice, p16Ink4a 
acts to promote age-related disease changes and cellular senescence, whereas p19Arf 
functions to suppress these alterations. 
 
After finding that BubR1 was integral in preventing premature age-related phenotypes, we 
were curious if other mitotic checkpoint deficient mouse models that exhibited similar rates 
of chromosome missegregation were also susceptible to these diseases. Although we found 
that Bub3/Rae1 compound haplo-insufficient animals do have a slight predisposition to 
development of premature aging, the time to onset is substantially delayed compared to 
BubR1 hypomorphic mice (Chapter 6). Bub3/Rae1 haplo-insufficient animals engage the 
Rb-p16Ink4a and p53-p19Arf pathway as well, but to a significantly lesser degree than 
hypomorphic BubR1 mice, suggesting that premature aging in mitotic checkpoint defective 
mouse models results from cellular senescence and hyperactivation of the pathways 
responsible for establishing this removal of cells from the cell cycle rather than from 
aneuploidy.  
 
Finally, we investigated the physiological role of the BubR1-related protein Bub1. Again 
we used knockout and hypomorphic mice to create a series of mice with graded reductions 
in Bub1 (Chapter 8). We find that while Bub1 is required for normal embryogenesis, low 
levels of this checkpoint protein do not result in premature age-related diseases. Consistent 
with our earlier work, these animals do not display cellular senescence or engagement of 
the Rb-p16Ink4a and p53-p19Arf pathways. However, unlike our previous models, Bub1 
insufficient mice are especially predisposed to spontaneous tumor formation. Cells that 
have low levels of Bub1 display high rates of chromosome missegregation, and unlike cells 
with a full complement of Bub1, increased rates of cellular survival following these 
segregation aberrancies. These results suggest that Bub1 functions as a tumor suppressor 
by both protecting cells from having missegregation events during mitosis and by 
promoting apoptosis in cells that happen to have undergone a defect in separation of 
chromosomes. 
 189 
Discussion and Future Outlook 
 
Defective mitotic checkpoint activity promotes the development of aneuploidy. Since 
nearly all human cancers exhibit this trait, many efforts looking for mutations in mitotic 
checkpoint genes in human cancer have been undertaken. However, the majority of these 
studies reveal no consistent mutations in the critical members of the mitotic checkpoint. 
More interestingly is the finding that certain members of this surveillance machinery are 
either overexpressed or downregulated in human cancer. Our results demonstrate that 
utilizing the mouse for testing the physiological relevance of mitotic checkpoint genes can 
result in some expected, but many more unexpected, functions of these genes. We have 
used hypomorphic mice in both our Bub1 and BubR1 studies, where we are able to bring 
the absolute level of expression of these genes below that which is seen in heterozygous 
null mice. Importantly, the phenotypes of spontaneous cancer predisposition in Bub1 mice 
and premature aging in BubR1 mice absolutely require these low levels. Many checkpoint 
models have strictly used a classical gene knockout approach, and have not come to the 
same findings. It may be interesting to go back to the established models and attempt to 
reduce the absolute level of each individual checkpoint protein to see if other members of 
the mitotic checkpoint machinery are able to recapitulate the results that we have obtained. 
Additionally, compound mutant mice lacking more than one checkpoint protein may yield 
unforeseen results, such as the earlier onset to age-related diseases in double haplo-
insufficient Bub3/Rae1 mice that we have reported.  
 
Many mitotic checkpoint defective models display a predisposition to tumor development 
when challenged with carcinogens. However, the actual mutations resulting from these 
treatments that are able to synergize in these animals have been elusive. Additionally, 
attempts to promote tumor formation in checkpoint defective mice by removing the tumor 
suppressors p53 or Rb have been ineffective [2]. Therefore, it will be of extreme interest 
and importance to determine what genes are able to cooperate with mitotic checkpoint 
deficiency to promote tumors and help provide a better understanding of the role of 
aneuploidy in cancer. Furthermore, these experiments may allow for identification of 
similar alterations that occur during the multi-step process of tumorigenesis in humans. 
Adding further complexity to the role that aneuploidy may have in tumorigenesis, it 
appears that under certain circumstances aneuploidy actually prevents the formation of 
cancer. CENP-E haploinsufficient mice, which develop high rates of aneuploidy both in 
vitro and in vivo, have higher rates of spontaneous tumors, while challenging these animals 
with a carcinogen decreases the number and size of tumors [3]. We have found that Bub1 
haploinsufficiency does synergize with carcinogen exposure to yield high rates of tumor 
formation (Chapter 8). However, these mice appear to be slightly protected from 
spontaneous tumors, implying that loss of one Bub1 gene can act to accelerate the 
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development of tumors initiated by particular gene mutations that may or may not require 
aneuploidy. Analysis of our series of Bub1 mutant mice establishes that reduced expression 
of Bub1 promotes spontaneous tumor formation, but only once the level has breached a 
critical threshold. Mice with the most dramatic reduction have the highest incidence of 
tumors, as well as the highest percentage of aneuploid cells. However, we find that animals 
that have similar rates of aneuploidy (i.e. Nup98/Rae1 double haploinsufficient and 
Bub3/Rae1 double haploinsufficient) do not have this same predisposition. What could be a 
potential reason for this discrepancy? Perhaps Bub1 hypomorphic mice are more prone to 
development of wide varieties of abnormal karyotypes because of decreased apoptosis 
following missegregation events. However, the role of aneuploidy in tumorigenesis, despite 
the fact that it is a nearly 100-year-old observation, remains highly complex. It will be 
necessary to examine each regulator of chromosome separation in order to clarify its role in 
tumorigenesis through the use of mouse models. These efforts may identify a smaller group 
of mitotic checkpoint proteins that are especially important for preventing cancer 
formation. Among these, there may be mitotic regulators that serve as hubs within the 
checkpoint or are connected to other molecular networks that are essential for protection 
against neoplastic transformation. 
 
The link between mitotic checkpoint impairment and cancer predisposition is supported by 
the finding that a high proportion of individuals with mosaic variegated aneuploidy (MVA) 
syndrome exhibit biallelic mutations in BubR1 [4]. These patients are especially 
susceptible to neoplasms such as rhabdomyosarcoma, Wilms tumor, and leukemia [5, 6]. 
Interestingly, these patients also develop a variety of other phenotypes, including 
microcephaly, growth retardation, and cataracts. Whether these patients develop other 
progeroid features remains to be established, as only four patients with BubR1 mutations 
have been identified, three of which are <3 yr of age. Because MVA is such a rare human 
syndrome, it may be necessary to use the mouse to model these biallelic mutations to learn 
more about the pathology of this syndrome and its possible link to premature aging. Almost 
all MVA patients carry one missense mutation in the kinase domain and a truncating 
mutation upstream of the kinase domain [4]. Therefore, a mouse model where the activity 
of the kinase domain of BubR1 is investigated would be extremely interesting.  
 
The expression of BubR1 declines with age in a variety of tissues in the mouse and mice 
with low levels of this gene develop a variety of early aging-related phenotypes. This 
suggests that BubR1 may be a determinant of natural aging. To test this idea, mice that 
carry transgenes of BubR1 to offset the natural decline in BubR1 could be used to see if 
forced overexpression can extend lifespan and prevent or delay aging-related disorders. 
These experiments may be complicated by an increased tumor formation, as it has been 
recently reported that mice which overexpress the mitotic checkpoint gene Mad2 are 
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susceptible to spontaneous tumor formation [7]. Additionally, if BubR1 transgenic mice are 
able to rescue the age-related pathology of BubR1 hypomorphic mice, additional 
transgenes lacking certain key domains of BubR1, including the kinase domain, could be 
utilized to determine what domains are critical for prevention of cancer and premature 
aging in hypomorphic BubR1 mice. The amount of BubR1 declines with age apparently 
due to decreased transcription, but the reason for this has not been determined. Therefore 
several key questions remain. What causes the silencing of the BubR1 gene? Is this process 
important for preventing the development of adverse conditions later in life? Are there 
active mechanisms in place to halt the transcription of BubR1 with age or is it simply the 
by-product of the aging process? These are obvious venues to explore in establishment of 
the critical functions that BubR1 has during normal organismal aging. 
 
By using BubR1 hypomorphic mice, we have been able to clearly define alternative age-
related pathologies in mice lacking the tumor suppressors p16Ink4a or p19Arf. Mice that have 
combined p16Ink4a deficiency along with low levels of BubR1 have substantial delays to 
age-related disease onset, suggesting that engagement of this tumor suppressor results in 
increased in vivo senescence and aging. Consistent with this, recent work has indicated that 
increased p16Ink4a expression contributes to age-related depletion of stem cell populations 
in the brain, pancreas and bone marrow [8-10]. Remarkably, disruption of the alternative 
reading frame product p19Arf in hypomorphic BubR1 mice accelerates the onset of aging, 
suggesting that p19Arf functions as an attenuator of in vivo senescence and aging. Recent 
work further supports this hypothesis, as mice which have increased, but normally 
regulated, levels of p19Arf and p53 have a strong resistance to cancer and have decreased 
levels of aging-associated damage [11]. Therefore, it will also be imperative to define the 
role of p53 itself in relation to aging in the context of BubR1 hypomorphic animals. So 
clearly, the role of BubR1, and other mitotic checkpoint genes, in aging and cancer are only 
beginning to be elucidated. 
 
One central question remains about aging in BubR1 hypomorphic mice: What is the 
primary nature of the stress causing the activation of senescence and aging? Initially, we 
thought that it may be aneuploidy, but have since ruled that out as the sole cause of aging 
by using many other mitotic checkpoint defective mouse models that also develop severe 
aneuploidy. We now believe that in certain tissues, the rates of aging correlate very closely 
with the induction of cellular senescence and engagement of these pathways. However, 
why do low amounts of BubR1 promote this response? DNA damage is believed to activate 
these same pathways, but we currently have no evidence for increased DNA damage or a 
defective ability to repair lesions in BubR1 hypomorphic cells. Single cell gel 
electrophoresis assays, also known as Comet assays, on hypomorphic BubR1 tissues 
reveals no increased single-strand or double strand breaks, apurinic or apyrimidinic sites, or 
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DNA adducts. Preliminary studies indicate BubR1 tissues that age prematurely have 
increased oxidative stress. If BubR1 hypomorphism indeed promotes the generation of 
reactive oxygen species (ROS), the next question would be, how would it do so? Also, the 
role that ROS has during organismal aging remains a topic of intense debate [12]. We are 
also exploring the possibility that there is oncogene induced senescence in BubR1 
hypomorphic mice. Perrhaps key oncogenes that are normally kept inactive when BubR1 is 
present at normal amounts are aberrantly signaling in conditions where BubR1 drops below 
a critical threshold level. The use of mass spectrometry may be useful to identify these 
unknown binding partners of BubR1 that may themselves be influential or essential in 
promotion of age-related disease. Obviously BubR1 has a pivotal role outside of its 
function during the mitotic checkpoint, but remains elusive. Hopefully, with good design, 
this pathway of aging stemming from deficiencies in BubR1 can be completed. 
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